Search

Your search keyword '"Ivano Baragetti"' showing total 40 results
Start Over Author "Ivano Baragetti"
40 results on '"Ivano Baragetti"'

1. Symptom Burden before and after Dialysis Initiation in Older Patients

Author

de Rooij, Esther N. M., Yvette, Meuleman, de Fijter, Johan W., Jager, Kitty J., Chesnaye, Nicholas C., Marie, Evans, Caskey, Fergus J., Claudia, Torino, Gaetana, Porto, Maciej, Szymczak, Christiane, Drechsler, Christoph, Wanner, Dekker, Friedo W., Hoogeveen, Ellen K., Andreas, Schneider, Anke, Torp, Beate, Iwig, Boris, Perras, Christian, Marx, Christof, Blaser, Claudia, Emde, Detlef, Krieter, Dunja, Fuchs, Ellen, Irmler, Eva, Platen, Hans, Schmidt-Gürtler, Hendrik, Schlee, Holger, Naujoks, Ines, Schlee, Sabine, Cäsar, Joachim, Beige, Jochen, Röthele, Justyna, Mazur, Kai, Hahn, Katja, Blouin, Katrin, Neumeier, Kirsten, Anding-Rost, Lothar, Schramm, Monika, Hopf, Nadja, Wuttke, Nikolaus, Frischmuth, Pawlos, Ichtiaris, Petra, Kirste, Petra, Schulz, Sabine, Aign, Sandra, Biribauer, Sherin, Manan, Silke, Röser, Stefan, Heidenreich, Stephanie, Palm, Susanne, Schwedler, Sylke, Delrieux, Sylvia, Renker, Sylvia, Schättel, Theresa, Stephan, Thomas, Schmiedeke, Thomas, Weinreich, Til, Leimbach, Torsten, Stövesand, Udo, Bahner, Wolfgang, Seeger, Cupisti, Adamasco, Adelia, Sagliocca, Alberto, Ferraro, Alessandra, Mele, Alessandro, Naticchia, Alex, Còsaro, Andrea, Ranghino, Andrea, Stucchi, Angelo, Pignataro, Antonella De Blasio, Antonello, Pani, Aris, Tsalouichos, Bellasi, Antonio, Biagio Raffaele Di Iorio, Butti, Alessandra, Cataldo, Abaterusso, Chiara, Somma, Claudia, D’Alessandro, Claudia, Zullo, Claudio, Pozzi, Daniela, Bergamo, Daniele, Ciurlino, Daria, Motta, Domenico, Russo, Enrico, Favaro, Federica, Vigotti, Ferruccio, Ansali, Ferruccio, Conte, Francesca, Cianciotta, Francesca, Giacchino, Francesco, Cappellaio, Francesco, Pizzarelli, Gaetano, Greco, Giada, Bigatti, Giancarlo, Marinangeli, Gianfranca, Cabiddu, Giordano, Fumagalli, Giorgia, Caloro, Giorgina, Piccoli, Giovanbattista, Capasso, Giovanni, Gambaro, Giuliana, Tognarelli, Giuseppe, Bonforte, Giuseppe, Conte, Giuseppe, Toscano, Goffredo Del Rosso, Irene, Capizzi, Ivano, Baragetti, Lamberto, Oldrizzi, Loreto, Gesualdo, Luigi, Biancone, Manuela, Magnano, Marco, Ricardi, Maria Di Bari, Maria, Laudato, Maria Luisa Sirico, Martina, Ferraresi, Michele, Provenzano, Moreno, Malaguti, Nicola, Palmieri, Paola, Murrone, Pietro, Cirillo, Pietro, Dattolo, Pina, Acampora, Rita, Nigro, Roberto, Boero, Roberto, Scarpioni, Rosa, Sicoli, Rosella, Malandra, Silvana, Savoldi, Silvio, Bertoli, Silvio, Borrelli, Stefania, Maxia, Stefano, Maffei, Stefano, Mangano, Teresa, Cicchetti, Tiziana, Rappa, Valentina, Palazzo, Walter De Simone, Anita, Schrander, Bastiaan van Dam, Carl, Siegert, Carlo, Gaillard, Charles, Beerenhout, Cornelis, Verburgh, Cynthia, Janmaat, Ellen, Hoogeveen, Ewout, Hoorn, Friedo, Dekker, Johannes, Boots, Henk, Boom, Jan-Willem, Eijgenraam, Jeroen, Kooman, Joris, Rotmans, Kitty, Jager, Liffert, Vogt, Maarten, Raasveld, Marc, Vervloet, Marjolijn van Buren, Merel van Diepen, Nicholas, Chesnaye, Paul, Leurs, Pauline, Voskamp, Peter, Blankestijn, Sadie van Esch, Siska, Boorsma, Stefan, Berger, Constantijn, Konings, Zeynep, Aydin, Aleksandra, Musiała, Anna, Szymczak, Ewelina, Olczyk, Hanna, Augustyniak-Bartosik, Ilona, Miśkowiec-Wiśniewska, Jacek, Manitius, Joanna, Pondel, Kamila, Jędrzejak, Katarzyna, Nowańska, Łukasz, Nowak, Magdalena, Durlik, Szyszkowska, Dorota, Teresa, Nieszporek, Zbigniew, Heleniak, Andreas, Jonsson, Anna-Lena, Blom, Björn, Rogland, Carin, Wallquist, Denes, Vargas, Emöke, Dimény, Fredrik, Sundelin, Fredrik, Uhlin, Gunilla, Welander, Isabel Bascaran Hernandez, Knut-Christian, Gröntoft, Maria, Stendahl, Maria, Svensson, Olof, Heimburger, Pavlos, Kashioulis, Stefan, Melander, Tora, Almquist, Ulrika, Jensen, Alistair, Woodman, Anna, Mckeever, Asad, Ullah, Barbara, Mclaren, Camille, Harron, Carla, Barrett, Charlotte, O'Toole, Christina, Summersgill, Colin, Geddes, Deborah, Glowski, Deborah, Mcglynn, Dympna, Sands, Fergus, Caskey, Geena, Roy, Gillian, Hirst, Hayley, King, Helen, Mcnally, Houda, Masri-Senghor, Hugh, Murtagh, Hugh, Rayner, Jane, Turner, Joanne, Wilcox, Jocelyn, Berdeprado, Jonathan, Wong, Joyce, Banda, Kirsteen, Jones, Lesley, Haydock, Lily, Wilkinson, Margaret, Carmody, Maria, Weetman, Martin, Joinson, Mary, Dutton, Michael, Matthews, Neal, Morgan, Nina, Bleakley, Paul, Cockwell, Paul, Roderick, Phil, Mason, Philip, Kalra, Rincy, Sajith, Sally, Chapman, Santee, Navjee, Sarah, Crosbie, Sharon, Brown, Sheila, Tickle, Suresh, Mathavakkannan, Ying, Kuan., Medical Informatics, APH - Aging & Later Life, APH - Quality of Care, APH - Methodology, APH - Global Health, APH - Health Behaviors & Chronic Diseases, and ACS - Pulmonary hypertension & thrombosis

Subjects
Transplantation, chronic kidney disease, dialysis, elderly, end stage kidney disease, epidemiology and outcomes, Nephrology, Epidemiology, Critical Care and Intensive Care Medicine
Abstract

Background and objectives For older patients with kidney failure, lowering symptom burden may be more important than prolonging life. Dialysis initiation may affect individual kidney failure-related symptoms differently, but the change in symptoms before and after start of dialysis has not been studied. Therefore, we investigated the course of total and individual symptom number and burden before and after starting dialysis in older patients.Design, setting, participants, & measurements The European Quality (EQUAL) study is an ongoing, prospective, multicenter study in patients >= 65 years with an incident eGFR

Published
2022
Full Text
View/download PDF

2. Predicting Kidney Failure, Cardiovascular Disease and Death in Advanced CKD Patients

Author

Chava L. Ramspek, Rosemarijn Boekee, Marie Evans, Olof Heimburger, Charlotte M. Snead, Fergus J. Caskey, Claudia Torino, Gaetana Porto, Maciej Szymczak, Magdalena Krajewska, Christiane Drechsler, Christoph Wanner, Nicholas C. Chesnaye, Kitty J. Jager, Friedo W. Dekker, Maarten G.J. Snoeijs, Joris I. Rotmans, Merel van Diepen, Adamasco Cupisti, Adelia Sagliocca, Alberto Ferraro, Aleksandra Musiała, Alessandra Mele, Alessandro Naticchia, Alex Còsaro, Alistair Woodman, Andrea Ranghino, Andrea Stucchi, Andreas Jonsson, Andreas Schneider, Angelo Pignataro, Anita Schrander, Anke Torp, Anna McKeever, Anna Szymczak, Anna-Lena Blom, Antonella De Blasio, Antonello Pani, Aris Tsalouichos, Asad Ullah, Barbara McLaren, Bastiaan van Dam, Beate Iwig, Bellasi Antonio, Biagio Raffaele Di Iorio, Björn Rogland, Boris Perras, Butti Alessandra, Camille Harron, Carin Wallquist, Carl Siegert, Carla Barrett, Carlo Gaillard, Carlo Garofalo, Cataldo Abaterusso, Charles Beerenhout, Charlotte O'Toole, Chiara Somma, Christian Marx, Christina Summersgill, Christof Blaser, Claudia D'alessandro, Claudia Emde, Claudia Zullo, Claudio Pozzi, Colin Geddes, Cornelis Verburgh, Daniela Bergamo, Daniele Ciurlino, Daria Motta, Deborah Glowski, Deborah McGlynn, Denes Vargas, Detlef Krieter, Domenico Russo, Dunja Fuchs, Dympna Sands, Ellen Hoogeveen, Ellen Irmler, Emöke Dimény, Enrico Favaro, Eva Platen, Ewelina Olczyk, Ewout Hoorn, Federica Vigotti, Ferruccio Ansali, Ferruccio Conte, Francesca Cianciotta, Francesca Giacchino, Francesco Cappellaio, Francesco Pizzarelli, Fredrik Sundelin, Fredrik Uhlin, Gaetano Greco, Geena Roy, Giada Bigatti, Giancarlo Marinangeli, Gianfranca Cabiddu, Gillian Hirst, Giordano Fumagalli, Giorgia Caloro, Giorgina Piccoli, Giovanbattista Capasso, Giovanni Gambaro, Giuliana Tognarelli, Giuseppe Bonforte, Giuseppe Conte, Giuseppe Toscano, Goffredo Del Rosso, Gunilla Welander, Hanna Augustyniak-Bartosik, Hans Boots, Hans Schmidt-Gürtler, Hayley King, Helen McNally, Hendrik Schlee, Henk Boom, Holger Naujoks, Houda Masri-Senghor, Hugh Murtagh, Hugh Rayner, Ilona Miśkowiec-Wiśniewska, Ines Schlee, Irene Capizzi, Isabel Bascaran Hernandez, Ivano Baragetti, Jacek Manitius, Jane Turner, Jan-Willem Eijgenraam, Jeroen Kooman, Joachim Beige, Joanna Pondel, Joanne Wilcox, Jocelyn Berdeprado, Jochen Röthele, Jonathan Wong, Joris Rotmans, Joyce Banda, Justyna Mazur, Kai Hahn, Kamila Jędrzejak, Katarzyna Nowańska, Katja Blouin, Katrin Neumeier, Kirsteen Jones, Kirsten Anding-Rost, Knut-Christian Gröntoft, Lamberto Oldrizzi, Lesley Haydock, Liffert Vogt, Lily Wilkinson, Loreto Gesualdo, Lothar Schramm, Luigi Biancone, Łukasz Nowak, Maarten Raasveld, Magdalena Durlik, Manuela Magnano, Marc Vervloet, Marco Ricardi, Margaret Carmody, Maria Di Bari, Maria Laudato, Maria Luisa Sirico, Maria Stendahl, Maria Svensson, Maria Weetman, Marjolijn van Buren, Martin Joinson, Martina Ferraresi, Mary Dutton, Michael Matthews, Michele Provenzano, Monika Hopf, Moreno Malaguti, Nadja Wuttke, Neal Morgan, Nicola Palmieri, Nikolaus Frischmuth, Nina Bleakley, Paola Murrone, Paul Cockwell, Paul Leurs, Paul Roderick, Pauline Voskamp, Pavlos Kashioulis, Pawlos Ichtiaris, Peter Blankestijn, Petra Kirste, Petra Schulz, Phil Mason, Philip Kalra, Pietro Cirillo, Pietro Dattolo, Pina Acampora, Rincy Sajith, Rita Nigro, Roberto Boero, Roberto Scarpioni, Rosa Sicoli, Rosella Malandra, Sabine Aign, Sabine Cäsar, Sadie van Esch, Sally Chapman, Sandra Biribauer, Santee Navjee, Sarah Crosbie, Sharon Brown, Sheila Tickle, Sherin Manan, Silke Röser, Silvana Savoldi, Silvio Bertoli, Silvio Borrelli, Siska Boorsma, Stefan Heidenreich, Stefan Melander, Stefania Maxia, Stefano Maffei, Stefano Mangano, Stephanie Palm, Stijn Konings, Suresh Mathavakkannan, Susanne Schwedler, Sylke Delrieux, Sylvia Renker, Sylvia Schättel, Szyszkowska Dorota, Teresa Cicchetti, Teresa Nieszporek, Theresa Stephan, Thomas Schmiedeke, Thomas Weinreich, Til Leimbach, Tiziana Rappa, Tora Almquist, Torsten Stövesand, Udo Bahner, Ulrika Jensen, Valentina Palazzo, Walter De Simone, Wolfgang Seeger, Ying Kuan, Zbigniew Heleniak, Zeynep Aydin, Vascular Surgery, MUMC+: MA Med Staf Spec Vaatchirurgie (9), RS: Carim - V03 Regenerative and reconstructive medicine vascular disease, Ramspek, C. L., Boekee, R., Evans, M., Heimburger, O., Snead, C. M., Caskey, F. J., Torino, C., Porto, G., Szymczak, M., Krajewska, M., Drechsler, C., Wanner, C., Chesnaye, N. C., Jager, K. J., Dekker, F. W., Snoeijs, M. G. J., Rotmans, J. I., van Diepen, M., Cupisti, A., Sagliocca, A., Ferraro, A., Musiala, A., Mele, A., Naticchia, A., Cosaro, A., Woodman, A., Ranghino, A., Stucchi, A., Jonsson, A., Schneider, A., Pignataro, A., Schrander, A., Torp, A., Mckeever, A., Szymczak, A., Blom, A. -L., De Blasio, A., Pani, A., Tsalouichos, A., Ullah, A., Mclaren, B., van Dam, B., Iwig, B., Antonio, B., Di Iorio, B. R., Rogland, B., Perras, B., Alessandra, B., Harron, C., Wallquist, C., Siegert, C., Barrett, C., Gaillard, C., Garofalo, C., Abaterusso, C., Beerenhout, C., O'Toole, C., Somma, C., Marx, C., Summersgill, C., Blaser, C., D'Alessandro, C., Emde, C., Zullo, C., Pozzi, C., Geddes, C., Verburgh, C., Bergamo, D., Ciurlino, D., Motta, D., Glowski, D., Mcglynn, D., Vargas, D., Krieter, D., Russo, D., Fuchs, D., Sands, D., Hoogeveen, E., Irmler, E., Dimeny, E., Favaro, E., Platen, E., Olczyk, E., Hoorn, E., Vigotti, F., Ansali, F., Conte, F., Cianciotta, F., Giacchino, F., Cappellaio, F., Pizzarelli, F., Sundelin, F., Uhlin, F., Greco, G., Roy, G., Bigatti, G., Marinangeli, G., Cabiddu, G., Hirst, G., Fumagalli, G., Caloro, G., Piccoli, G., Capasso, G., Gambaro, G., Tognarelli, G., Bonforte, G., Conte, G., Toscano, G., Del Rosso, G., Welander, G., Augustyniak-Bartosik, H., Boots, H., Schmidt-Gurtler, H., King, H., Mcnally, H., Schlee, H., Boom, H., Naujoks, H., Masri-Senghor, H., Murtagh, H., Rayner, H., Miskowiec-Wisniewska, I., Schlee, I., Capizzi, I., Hernandez, I. B., Baragetti, I., Manitius, J., Turner, J., Eijgenraam, J. -W., Kooman, J., Beige, J., Pondel, J., Wilcox, J., Berdeprado, J., Rothele, J., Wong, J., Rotmans, J., Banda, J., Mazur, J., Hahn, K., Jedrzejak, K., Nowanska, K., Blouin, K., Neumeier, K., Jones, K., Anding-Rost, K., Grontoft, K. -C., Oldrizzi, L., Haydock, L., Vogt, L., Wilkinson, L., Gesualdo, L., Schramm, L., Biancone, L., Nowak, L., Raasveld, M., Durlik, M., Magnano, M., Vervloet, M., Ricardi, M., Carmody, M., Di Bari, M., Laudato, M., Sirico, M. L., Stendahl, M., Svensson, M., Weetman, M., van Buren, M., Joinson, M., Ferraresi, M., Dutton, M., Matthews, M., Provenzano, M., Hopf, M., Malaguti, M., Wuttke, N., Morgan, N., Palmieri, N., Frischmuth, N., Bleakley, N., Murrone, P., Cockwell, P., Leurs, P., Roderick, P., Voskamp, P., Kashioulis, P., Ichtiaris, P., Blankestijn, P., Kirste, P., Schulz, P., Mason, P., Kalra, P., Cirillo, P., Dattolo, P., Acampora, P., Sajith, R., Nigro, R., Boero, R., Scarpioni, R., Sicoli, R., Malandra, R., Aign, S., Casar, S., van Esch, S., Chapman, S., Biribauer, S., Navjee, S., Crosbie, S., Brown, S., Tickle, S., Manan, S., Roser, S., Savoldi, S., Bertoli, S., Borrelli, S., Boorsma, S., Heidenreich, S., Melander, S., Maxia, S., Maffei, S., Mangano, S., Palm, S., Konings, S., Mathavakkannan, S., Schwedler, S., Delrieux, S., Renker, S., Schattel, S., Dorota, S., Cicchetti, T., Nieszporek, T., Stephan, T., Schmiedeke, T., Weinreich, T., Leimbach, T., Rappa, T., Almquist, T., Stovesand, T., Bahner, U., Jensen, U., Palazzo, V., De Simone, W., Seeger, W., Kuan, Y., Heleniak, Z., Aydin, Z., Medical Informatics, APH - Aging & Later Life, APH - Methodology, APH - Quality of Care, Nephrology, ACS - Microcirculation, APH - Health Behaviors & Chronic Diseases, APH - Global Health, ACS - Pulmonary hypertension & thrombosis, ACS - Diabetes & metabolism, and Internal Medicine

Subjects
SDG 3 - Good Health and Well-being, external validation, Nephrology, cardiovascular disease, death, CKD, kidney failure, prognostic model
Abstract

Introduction: Predicting the timing and occurrence of kidney replacement therapy (KRT), cardiovascular events, and death among patients with advanced chronic kidney disease (CKD) is clinically useful and relevant. We aimed to externally validate a recently developed CKD G4+ risk calculator for these outcomes and to assess its potential clinical impact in guiding vascular access placement. Methods: We included 1517 patients from the European Quality (EQUAL) study, a European multicentre prospective cohort study of nephrology-referred advanced CKD patients aged ≥65 years. Model performance was assessed based on discrimination and calibration. Potential clinical utility for timing of referral for vascular access placement was studied with diagnostic measures and decision curve analysis (DCA). Results: The model showed a good discrimination for KRT and “death after KRT,” with 2-year concordance (C) statistics of 0.74 and 0.76, respectively. Discrimination for cardiovascular events (2-year C-statistic: 0.70) and overall death (2-year C-statistic: 0.61) was poorer. Calibration was fairly accurate. Decision curves illustrated that using the model to guide vascular access referral would generally lead to less unused arteriovenous fistulas (AVFs) than following estimated glomerular filtration rate (eGFR) thresholds. Conclusion: This study shows moderate to good predictive performance of the model in an older cohort of nephrology-referred patients with advanced CKD. Using the model to guide referral for vascular access placement has potential in combating unnecessary vascular surgeries.

Published
2022
Full Text
View/download PDF

3. Kidney failure prediction models

Author

Ramspek, Chava L, Evans, Marie, Wanner, Christoph, Drechsler, Christiane, Chesnaye, Nicholas C, Szymczak, Maciej, Krajewska, Magdalena, Torino, Claudia, Porto, Gaetana, Hayward, Samantha, Caskey, Fergus, Dekker, Friedo W, Jager, Kitty J, van Diepen, Merel, EQUAL Study Investigators: Adamasco Cupisti, Adelia Sagliocca, Alberto Ferraro, Aleksandra Musiała, Alessandra Mele, Alessandro Naticchia, Alex Còsaro, Alistair Woodman, Andrea Ranghino, Andrea Stucchi, Andreas Jonsson, Andreas Schneider, Angelo Pignataro, Anita Schrander, Anke Torp, Anna McKeever, Anna Szymczak, Anna-Lena Blom, Antonella De Blasio, Antonello Pani, Aris Tsalouichos, Asad Ullah, Barbara McLaren, Bastiaan van Dam, Beate Iwig, Bellasi Antonio, Biagio Raffaele Di Iorio, Björn Rogland, Boris Perras, Butti Alessandra, Camille Harron, Carin Wallquist, Carl Siegert, Carla Barrett, Carlo Gaillard, Carlo Garofalo, Cataldo Abaterusso, Charles Beerenhout, Charlotte O'Toole, Chiara Somma, Christian Marx, Christina Summersgill, Christof Blaser, Claudia D'alessandro, Claudia Emde, Claudia Zullo, Claudio Pozzi, Colin Geddes, Cornelis Verburgh, Daniela Bergamo, Daniele Ciurlino, Daria Motta, Deborah Glowski, Deborah McGlynn, Denes Vargas, Detlef Krieter, Domenico Russo, Dunja Fuchs, Dympna Sands, Ellen Hoogeveen, Ellen Irmler, Emöke Dimény, Enrico Favaro, Eva Platen, Ewelina Olczyk, Ewout Hoorn, Federica Vigotti, Ferruccio Ansali, Ferruccio Conte, Francesca Cianciotta, Francesca Giacchino, Francesco Cappellaio, Francesco Pizzarelli, Fredrik Sundelin, Fredrik Uhlin, Gaetano Greco, Geena Roy, Gaetana Porto, Giada Bigatti, Giancarlo Marinangeli, Gianfranca Cabiddu, Gillian Hirst, Giordano Fumagalli, Giorgia Caloro, Giorgina Piccoli, Giovanbattista Capasso, Giovanni Gambaro, Giuliana Tognarelli, Giuseppe Bonforte, Giuseppe Conte, Giuseppe Toscano, Goffredo Del Rosso, Gunilla Welander, Hanna Augustyniak-Bartosik, Hans Boots, Hans Schmidt-Gürtler, Hayley King, Helen McNally, Hendrik Schlee, Henk Boom, Holger Naujoks, Houda Masri-Senghor, Hugh Murtagh, Hugh Rayner, Ilona Miśkowiec-Wiśniewska, Ines Schlee, Irene Capizzi, Isabel Bascaran Hernandez, Ivano Baragetti, Jacek Manitius, Jane Turner, Jan-Willem Eijgenraam, Jeroen Kooman, Joachim Beige, Joanna Pondel, Joanne Wilcox, Jocelyn Berdeprado, Jochen Röthele, Jonathan Wong, Joris Rotmans, Joyce Banda, Justyna Mazur, Kai Hahn, Kamila Jędrzejak, Katarzyna Nowańska, Katja Blouin, Katrin Neumeier, Kirsteen Jones, Kirsten Anding-Rost, Knut-Christian Gröntoft, Lamberto Oldrizzi, Lesley Haydock, Liffert Vogt, Lily Wilkinson, Loreto Gesualdo, Lothar Schramm, Luigi Biancone, Łukasz Nowak, Maarten Raasveld, Magdalena Durlik, Manuela Magnano, Marc Vervloet, Marco Ricardi, Margaret Carmody, Maria Di Bari, Maria Laudato, Maria Luisa Sirico, Maria Stendahl, Maria Svensson, Maria Weetman, Marjolijn van Buren, Martin Joinson, Martina Ferraresi, Mary Dutton, Merel van Diepen, Michael Matthews, Michele Provenzano, Monika Hopf, Moreno Malaguti, Nadja Wuttke, Neal Morgan, Nicola Palmieri, Nikolaus Frischmuth, Nina Bleakley, Paola Murrone, Paul Cockwell, Paul Leurs, Paul Roderick, Pauline Voskamp, Pavlos Kashioulis, Pawlos Ichtiaris, Peter Blankestijn, Petra Kirste, Petra Schulz, Phil Mason, Philip Kalra, Pietro Cirillo, Pietro Dattolo, Pina Acampora, Rincy Sajith, Rita Nigro, Roberto Boero, Roberto Scarpioni, Rosa Sicoli, Rosella Malandra, Sabine Aign, Sabine Cäsar, Sadie van Esch, Sally Chapman, Sandra Biribauer, Santee Navjee, Sarah Crosbie, Sharon Brown, Sheila Tickle, Sherin Manan, Silke Röser, Silvana Savoldi, Silvio Bertoli, Silvio Borrelli, Siska Boorsma, Stefan Heidenreich, Stefan Melander, Stefania Maxia, Stefano Maffei, Stefano Mangano, Stephanie Palm, Stijn Konings, Suresh Mathavakkannan, Susanne Schwedler, Sylke Delrieux, Sylvia Renker, Sylvia Schättel, Szyszkowska Dorota, Teresa Cicchetti, Teresa Nieszporek, Theresa Stephan, Thomas Schmiedeke, Thomas Weinreich, Til Leimbach, Tiziana Rappa, Tora Almquist, Torsten Stövesand, Udo Bahner, Ulrika Jensen, Valentina Palazzo, Walter De Simone, Wolfgang Seeger, Ying Kuan, Zbigniew Heleniak, Zeynep Aydin, Internal Medicine, Chava L, Ramspek, Marie, Evan, Christoph, Wanner, Christiane, Drechsler, Nicholas C, Chesnaye, Maciej, Szymczak, Magdalena, Krajewska, Claudia, Torino, Gaetana, Porto, Samantha, Hayward, Fergus, Caskey, Friedo W, Dekker, Kitty J, Jager, Merel, van Diepen, Study Investigators: Adamasco Cupisti, Equal, Sagliocca, Adelia, Ferraro, Alberto, Musiała, Aleksandra, Mele, Alessandra, Naticchia, Alessandro, Còsaro, Alex, Woodman, Alistair, Ranghino, Andrea, Stucchi, Andrea, Jonsson, Andrea, Schneider, Andrea, Pignataro, Angelo, Schrander, Anita, Torp, Anke, Mckeever, Anna, Szymczak, Anna, Blom, Anna-Lena, De Blasio, Antonella, Pani, Antonello, Tsalouichos, Ari, Ullah, Asad, Mclaren, Barbara, van Dam, Bastiaan, Iwig, Beate, Antonio, Bellasi, Raffaele Di Iorio, Biagio, Rogland, Björn, Perras, Bori, Alessandra, Butti, Harron, Camille, Wallquist, Carin, Siegert, Carl, Barrett, Carla, Gaillard, Carlo, Garofalo, Carlo, Abaterusso, Cataldo, Beerenhout, Charle, O'Toole, Charlotte, Somma, Chiara, Marx, Christian, Summersgill, Christina, Blaser, Christof, D'Alessandro, Claudia, Emde, Claudia, Zullo, Claudia, Pozzi, Claudio, Geddes, Colin, Verburgh, Corneli, Bergamo, Daniela, Ciurlino, Daniele, Motta, Daria, Glowski, Deborah, Mcglynn, Deborah, Vargas, Dene, Krieter, Detlef, Russo, Domenico, Fuchs, Dunja, Sands, Dympna, Hoogeveen, Ellen, Irmler, Ellen, Dimény, Emöke, Favaro, Enrico, Platen, Eva, Olczyk, Ewelina, Hoorn, Ewout, Vigotti, Federica, Ansali, Ferruccio, Conte, Ferruccio, Cianciotta, Francesca, Giacchino, Francesca, Cappellaio, Francesco, Pizzarelli, Francesco, Sundelin, Fredrik, Uhlin, Fredrik, Greco, Gaetano, Roy, Geena, Porto, Gaetana, Bigatti, Giada, Marinangeli, Giancarlo, Cabiddu, Gianfranca, Hirst, Gillian, Fumagalli, Giordano, Caloro, Giorgia, Piccoli, Giorgina, Capasso, Giovanbattista, Gambaro, Giovanni, Tognarelli, Giuliana, Bonforte, Giuseppe, Conte, Giuseppe, Toscano, Giuseppe, Del Rosso, Goffredo, Welander, Gunilla, Augustyniak-Bartosik, Hanna, Boots, Han, Schmidt-Gürtler, Han, King, Hayley, Mcnally, Helen, Schlee, Hendrik, Boom, Henk, Naujoks, Holger, Masri-Senghor, Houda, Murtagh, Hugh, Rayner, Hugh, Miśkowiec-Wiśniewska, Ilona, Schlee, Ine, Capizzi, Irene, Bascaran Hernandez, Isabel, Baragetti, Ivano, Manitius, Jacek, Turner, Jane, Eijgenraam, Jan-Willem, Kooman, Jeroen, Beige, Joachim, Pondel, Joanna, Wilcox, Joanne, Berdeprado, Jocelyn, Röthele, Jochen, Wong, Jonathan, Rotmans, Jori, Banda, Joyce, Mazur, Justyna, Hahn, Kai, Jędrzejak, Kamila, Nowańska, Katarzyna, Blouin, Katja, Neumeier, Katrin, Jones, Kirsteen, Anding-Rost, Kirsten, Gröntoft, Knut-Christian, Oldrizzi, Lamberto, Haydock, Lesley, Vogt, Liffert, Wilkinson, Lily, Gesualdo, Loreto, Schramm, Lothar, Biancone, Luigi, Nowak, Łukasz, Raasveld, Maarten, Durlik, Magdalena, Magnano, Manuela, Vervloet, Marc, Ricardi, Marco, Carmody, Margaret, Di Bari, Maria, Laudato, Maria, Luisa Sirico, Maria, Stendahl, Maria, Svensson, Maria, Weetman, Maria, van Buren, Marjolijn, Joinson, Martin, Ferraresi, Martina, Dutton, Mary, van Diepen, Merel, Matthews, Michael, Provenzano, Michele, Hopf, Monika, Malaguti, Moreno, Wuttke, Nadja, Morgan, Neal, Palmieri, Nicola, Frischmuth, Nikolau, Bleakley, Nina, Murrone, Paola, Cockwell, Paul, Leurs, Paul, Roderick, Paul, Voskamp, Pauline, Kashioulis, Pavlo, Ichtiaris, Pawlo, Blankestijn, Peter, Kirste, Petra, Schulz, Petra, Mason, Phil, Kalra, Philip, Cirillo, Pietro, Dattolo, Pietro, Acampora, Pina, Sajith, Rincy, Nigro, Rita, Boero, Roberto, Scarpioni, Roberto, Sicoli, Rosa, Malandra, Rosella, Aign, Sabine, Cäsar, Sabine, van Esch, Sadie, Chapman, Sally, Biribauer, Sandra, Navjee, Santee, Crosbie, Sarah, Brown, Sharon, Tickle, Sheila, Manan, Sherin, Röser, Silke, Savoldi, Silvana, Bertoli, Silvio, Borrelli, Silvio, Boorsma, Siska, Heidenreich, Stefan, Melander, Stefan, Maxia, Stefania, Maffei, Stefano, Mangano, Stefano, Palm, Stephanie, Konings, Stijn, Mathavakkannan, Suresh, Schwedler, Susanne, Delrieux, Sylke, Renker, Sylvia, Schättel, Sylvia, Dorota, Szyszkowska, Cicchetti, Teresa, Nieszporek, Teresa, Stephan, Theresa, Schmiedeke, Thoma, Weinreich, Thoma, Leimbach, Til, Rappa, Tiziana, Almquist, Tora, Stövesand, Torsten, Bahner, Udo, Jensen, Ulrika, Palazzo, Valentina, De Simone, Walter, Seeger, Wolfgang, Kuan, Ying, Heleniak, Zbigniew, Aydin, Zeynep, Medical Informatics, ACS - Pulmonary hypertension & thrombosis, APH - Aging & Later Life, APH - Health Behaviors & Chronic Diseases, APH - Methodology, APH - Quality of Care, and APH - Global Health

Subjects
Male, progression of chronic renal failure, medicine.medical_specialty, Time Factors, epidemiology and outcome, 030232 urology & nephrology, Risk Assessment, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Older patients, external validation, Predictive Value of Tests, medicine, Humans, Failure risk, Clinical Epidemiology, In patient, comprehensive external validation, 030212 general & internal medicine, Statistic, Aged, Aged, 80 and over, Kidney, Models, Statistical, business.industry, External validation, General Medicine, prediction, kidney failure, Europe, prediction model, medicine.anatomical_structure, chronic kidney disease, epidemiology and outcomes, prognosis, Nephrology, Emergency medicine, Disease Progression, Kidney Failure, Chronic, Female, business, prognostic, Predictive modelling, prognosi, Cohort study
Abstract

Background Various prediction models have been developed to predict the risk of kidney failure in patients with CKD. However, guideline-recommended models have yet to be compared head to head, their validation in patients with advanced CKD is lacking, and most do not account for competing risks. Methods To externally validate 11 existing models of kidney failure, taking the competing risk of death into account, we included patients with advanced CKD from two large cohorts: the European Quality Study (EQUAL), an ongoing European prospective, multicenter cohort study of older patients with advanced CKD, and the Swedish Renal Registry (SRR), an ongoing registry of nephrology-referred patients with CKD in Sweden. The outcome of the models was kidney failure (defined as RRT-treated ESKD). We assessed model performance with discrimination and calibration. Results The study included 1580 patients from EQUAL and 13,489 patients from SRR. The average c statistic over the 11 validated models was 0.74 in EQUAL and 0.80 in SRR, compared with 0.89 in previous validations. Most models with longer prediction horizons overestimated the risk of kidney failure considerably. The 5-year Kidney Failure Risk Equation (KFRE) overpredicted risk by 10%-\18%. The four- and eight-variable 2-year KFRE and the 4-year Grams model showed excellent calibration and good discrimination in both cohorts. Conclusions Some existing models can accurately predict kidney failure in patients with advanced CKD. KFRE performed well for a shorter time frame (2 years), despite not accounting for competing events. Models predicting over a longer time frame (5 years) overestimated risk because of the competing risk of death. The Grams model, which accounts for the latter, is suitable for longer-term predictions (4 years).

Published
2021
Full Text
View/download PDF

4. Associations between depressive symptoms and disease progression in older patients with chronic kidney disease

Author

Eveleens Maarse, Boukje C., Chesnaye, Nicholas C., Robbert, Schouten, Michels, Wieneke M., Bos, Willem Jan W., Maciej, Szymczak, Magdalena, Krajewska, Marie Evans, Olof Heimburger, Caskey, Fergus J., Christoph, Wanner, Jager, Kitty J., Dekker, Friedo W., Yvette, Meuleman, Andreas, Schneider, Anke, Torp, Beate, Iwig, Boris, Perras, Christian, Marx, Christiane, Drechsler, Christof, Blaser, Claudia, Emde, Detlef, Krieter, Dunja, Fuchs, Ellen, Irmler, Eva, Platen, Hans, Schmidt-Gürtler, Hendrik, Schlee, Holger, Naujoks, Ines, Schlee, Sabine, Cäsar, Joachim, Beige, Jochen, Röthele, Justyna, Mazur, Kai, Hahn, Katja, Blouin, Katrin, Neumeier, Kirsten, Anding-Rost, Lothar, Schramm, Monika, Hopf, Nadja, Wuttke, Nikolaus, Frischmuth, Pawlos, Ichtiaris, Petra, Kirste, Petra, Schulz, Sabine, Aign, Sandra, Biribauer, Sherin, Manan, Silke, Röser, Stefan, Heidenreich, Stephanie, Palm, Susanne, Schwedler, Sylke, Delrieux, Sylvia, Renker, Sylvia, Schättel, Theresa, Stephan, Thomas, Schmiedeke, Thomas, Weinreich, Til, Leimbach, Torsten, Stövesand, Udo, Bahner, Wolfgang, Seeger, Cupisti, Adamasco, Adelia, Sagliocca, Alberto, Ferraro, Alessandra, Mele, Alessandro, Naticchia, Alex, Còsaro, Andrea, Ranghino, Andrea, Stucchi, Angelo, Pignataro, Antonella De Blasio, Antonello, Pani, Aris, Tsalouichos, Bellasi, Antonio, Biagio Raffaele Di Iorio, Butti, Alessandra, Cataldo, Abaterusso, Chiara, Somma, Claudia, D'Alessandro, Claudia, Torino, Claudia, Zullo, Claudio, Pozzi, Daniela, Bergamo, Daniele, Ciurlino, Daria, Motta, Domenico, Russo, Enrico, Favaro, Federica, Vigotti, Ferruccio, Ansali, Ferruccio, Conte, Francesca, Cianciotta, Francesca, Giacchino, Francesco, Cappellaio, Francesco, Pizzarelli, Gaetano, Greco, Gaetana, Porto, Giada, Bigatti, Giancarlo, Marinangeli, Gianfranca, Cabiddu, Giordano, Fumagalli, Giorgia, Caloro, Giorgina, Piccoli, Giovanbattista, Capasso, Giovanni, Gambaro, Giuliana, Tognarelli, Giuseppe, Bonforte, Giuseppe, Conte, Giuseppe, Toscano, Goffredo Del Rosso, Irene, Capizzi, Ivano, Baragetti, Lamberto, Oldrizzi, Loreto, Gesualdo, Luigi, Biancone, Manuela, Magnano, Marco, Ricardi, Maria Di Bari, Maria, Laudato, Maria Luisa Sirico, Martina, Ferraresi, Maurizio, Postorino, Michele, Provenzano, Moreno, Malaguti, Nicola, Palmieri, Paola, Murrone, Pietro, Cirillo, Pietro, Dattolo, Pina, Acampora, Rita, Nigro, Roberto, Boero, Roberto, Scarpioni, Rosa, Sicoli, Rosella, Malandra, Silvana, Savoldi, Silvio, Bertoli, Silvio, Borrelli, Stefania, Maxia, Stefano, Maffei, Stefano, Mangano, Teresa, Cicchetti, Tiziana, Rappa, Valentina, Palazzo, Walter De Simone, Anita, Schrander, Bastiaan van Dam, Carl, Siegert, Carlo, Gaillard, Charles, Beerenhout, Cornelis, Verburgh, Cynthia, Janmaat, Ellen, Hoogeveen, Ewout, Hoorn, Friedo, Dekker, Johannes, Boots, Henk, Boom, Jan-Willem, Eijgenraam, Jeroen, Kooman, Joris, Rotmans, Kitty, Jager, Liffert, Vogt, Maarten, Raasveld, Marc, Vervloet, Marjolijn van Buren, Merel van Diepen, Nicholas, Chesnaye, Paul, Leurs, Pauline, Voskamp, Peter, Blankestijn, Sadie van Esch, Siska, Boorsma, Stefan, Berger, Constantijn, Konings, Zeynep, Aydin, Aleksandra, Musiała, Anna, Szymczak, Ewelina, Olczyk, Hanna, Augustyniak-Bartosik, Ilona, Miśkowiec-Wiśniewska, Jacek, Manitius, Joanna, Pondel, Kamila, Jędrzejak, Katarzyna, Nowańska, Łukasz, Nowak, Magdalena, Durlik, Szyszkowska, Dorota, Teresa, Nieszporek, Zbigniew, Heleniak, Andreas, Jonsson, Anna-Lena, Blom, Björn, Rogland, Carin, Wallquist, Denes, Vargas, Emöke, Dimény, Fredrik, Sundelin, Fredrik, Uhlin, Gunilla, Welander, Isabel Bascaran Hernandez, Knut-Christian, Gröntoft, Maria, Stendahl, Maria, Svensson, Marie, Evans, Olof, Heimburger, Pavlos, Kashioulis, Stefan, Melander, Tora, Almquist, Ulrika, Jensen, Alistair, Woodman, Anna, Mckeever, Asad, Ullah, Barbara, Mclaren, Camille, Harron, Carla, Barrett, Charlotte, O'Toole, Christina, Summersgill, Colin, Geddes, Deborah, Glowski, Deborah, Mcglynn, Dympna, Sands, Fergus, Caskey, Geena, Roy, Gillian, Hirst, Hayley, King, Helen, Mcnally, Houda, Masri-Senghor, Hugh, Murtagh, Hugh, Rayner, Jane, Turner, Joanne, Wilcox, Jocelyn, Berdeprado, Jonathan, Wong, Joyce, Banda, Kirsteen, Jones, Lesley, Haydock, Lily, Wilkinson, Margaret, Carmody, Maria, Weetman, Martin, Joinson, Mary, Dutton, Michael, Matthews, Neal, Morgan, Nina, Bleakley, Paul, Cockwell, Paul, Roderick, Phil, Mason, Philip, Kalra, Rincy, Sajith, Sally, Chapman, Santee, Navjee, Sarah, Crosbie, Sharon, Brown, Sheila, Tickle, Suresh, Mathavakkannan, Ying, Kuan, Internal medicine, Nephrology, ACS - Diabetes & metabolism, Medical Informatics, APH - Methodology, APH - Aging & Later Life, Graduate School, APH - Quality of Care, ACS - Microcirculation, APH - Health Behaviors & Chronic Diseases, APH - Global Health, ACS - Pulmonary hypertension & thrombosis, Eveleens Maarse, B. C., Chesnaye, N. C., Schouten, R., Michels, W. M., Bos, W. J. W., Szymczak, M., Krajewska, M., Evans, M., Heimburger, O., Caskey, F. J., Wanner, C., Jager, K. J., Dekker, F. W., Meuleman, Y., Schneider, A., Torp, A., Iwig, B., Perras, B., Marx, C., Drechsler, C., Blaser, C., Emde, C., Krieter, D., Fuchs, D., Irmler, E., Platen, E., Schmidt-Gurtler, H., Schlee, H., Naujoks, H., Schlee, I., Casar, S., Beige, J., Rothele, J., Mazur, J., Hahn, K., Blouin, K., Neumeier, K., Anding-Rost, K., Schramm, L., Hopf, M., Wuttke, N., Frischmuth, N., Ichtiaris, P., Kirste, P., Schulz, P., Aign, S., Biribauer, S., Manan, S., Roser, S., Heidenreich, S., Palm, S., Schwedler, S., Delrieux, S., Renker, S., Schattel, S., Stephan, T., Schmiedeke, T., Weinreich, T., Leimbach, T., Stovesand, T., Bahner, U., Seeger, W., Cupisti, A., Sagliocca, A., Ferraro, A., Mele, A., Naticchia, A., Cosaro, A., Ranghino, A., Stucchi, A., Pignataro, A., De Blasio, A., Pani, A., Tsalouichos, A., Antonio, B., Raffaele Di Iorio, B., Alessandra, B., Abaterusso, C., Somma, C., D'Alessandro, C., Torino, C., Zullo, C., Pozzi, C., Bergamo, D., Ciurlino, D., Motta, D., Russo, D., Favaro, E., Vigotti, F., Ansali, F., Conte, F., Cianciotta, F., Giacchino, F., Cappellaio, F., Pizzarelli, F., Greco, G., Porto, G., Bigatti, G., Marinangeli, G., Cabiddu, G., Fumagalli, G., Caloro, G., Piccoli, G., Capasso, G., Gambaro, G., Tognarelli, G., Bonforte, G., Conte, G., Toscano, G., Del Rosso, G., Capizzi, I., Baragetti, I., Oldrizzi, L., Gesualdo, L., Biancone, L., Magnano, M., Ricardi, M., Di Bari, M., Laudato, M., Luisa Sirico, M., Ferraresi, M., Postorino, M., Provenzano, M., Malaguti, M., Palmieri, N., Murrone, P., Cirillo, P., Dattolo, P., Acampora, P., Nigro, R., Boero, R., Scarpioni, R., Sicoli, R., Malandra, R., Savoldi, S., Bertoli, S., Borrelli, S., Maxia, S., Maffei, S., Mangano, S., Cicchetti, T., Rappa, T., Palazzo, V., De Simone, W., Schrander, A., Van Dam, B., Siegert, C., Gaillard, C., Beerenhout, C., Verburgh, C., Janmaat, C., Hoogeveen, E., Hoorn, E., Boots, J., Boom, H., Eijgenraam, J. -W., Kooman, J., Rotmans, J., Vogt, L., Raasveld, M., Vervloet, M., Van Buren, M., Van Diepen, M., Leurs, P., Voskamp, P., Blankestijn, P., Van Esch, S., Boorsma, S., Berger, S., Konings, C., Aydin, Z., Musiala, A., Szymczak, A., Olczyk, E., Augustyniak-Bartosik, H., Miskowiec-Wisniewska, I., Manitius, J., Pondel, J., Jedrzejak, K., Nowanska, K., Nowak, L., Durlik, M., Dorota, S., Nieszporek, T., Heleniak, Z., Jonsson, A., Blom, A. -L., Rogland, B., Wallquist, C., Vargas, D., Dimeny, E., Sundelin, F., Uhlin, F., Welander, G., Bascaran Hernandez, I., Grontoft, K. -C., Stendahl, M., Svensson, M., Kashioulis, P., Melander, S., Almquist, T., Jensen, U., Woodman, A., Mckeever, A., Ullah, A., Mclaren, B., Harron, C., Barrett, C., O'Toole, C., Summersgill, C., Geddes, C., Glowski, D., Mcglynn, D., Sands, D., Roy, G., Hirst, G., King, H., Mcnally, H., Masri-Senghor, H., Murtagh, H., Rayner, H., Turner, J., Wilcox, J., Berdeprado, J., Wong, J., Banda, J., Jones, K., Haydock, L., Wilkinson, L., Carmody, M., Weetman, M., Joinson, M., Dutton, M., Matthews, M., Morgan, N., Bleakley, N., Cockwell, P., Roderick, P., Mason, P., Kalra, P., Sajith, R., Chapman, S., Navjee, S., Crosbie, S., Brown, S., Tickle, S., Mathavakkannan, S., and Kuan, Y.

Subjects
Transplantation, prospective cohort study, depressive symptoms, nephrology care, Nephrology, clinical outcome, chronic kidney disease, clinical trial, epidemiology, joint model, survival analysis, depressive symptom
Abstract

Background Depressive symptoms are associated with adverse clinical outcomes in patients with end-stage kidney disease; however, few small studies have examined this association in patients with earlier phases of chronic kidney disease (CKD). We studied associations between baseline depressive symptoms and clinical outcomes in older patients with advanced CKD and examined whether these associations differed depending on sex. Methods CKD patients (≥65 years; estimated glomerular filtration rate ≤20 mL/min/1.73 m2) were included from a European multicentre prospective cohort between 2012 and 2019. Depressive symptoms were measured by the five-item Mental Health Inventory (cut-off ≤70; 0–100 scale). Cox proportional hazard analysis was used to study associations between depressive symptoms and time to dialysis initiation, all-cause mortality and these outcomes combined. A joint model was used to study the association between depressive symptoms and kidney function over time. Analyses were adjusted for potential baseline confounders. Results Overall kidney function decline in 1326 patients was –0.12 mL/min/1.73 m2/month. A total of 515 patients showed depressive symptoms. No significant association was found between depressive symptoms and kidney function over time (P = 0.08). Unlike women, men with depressive symptoms had an increased mortality rate compared with those without symptoms [adjusted hazard ratio 1.41 (95% confidence interval 1.03–1.93)]. Depressive symptoms were not significantly associated with a higher hazard of dialysis initiation, or with the combined outcome (i.e. dialysis initiation and all-cause mortality). Conclusions There was no significant association between depressive symptoms at baseline and decline in kidney function over time in older patients with advanced CKD. Depressive symptoms at baseline were associated with a higher mortality rate in men.

Published
2022
Full Text
View/download PDF

5. The association between TMAO, CMPF and clinical outcomes in advanced CKD; results from the EQUAL study

Author

Dai, Lu, Ziad, A Massy, Peter, Stenvinkel, Nicholas, C Chesnaye, Islam Amine Larabi, Jean Claude Alvarez, Fergus, J Caskey, Claudia, Torino, Gaetana, Porto, Maciej, Szymczak, Magdalena, Krajewska, Christiane, Drechsler, Christoph, Wanner, Kitty, J Jager, Friedo, W Dekker, Pieter, Evenepoel, Marie, Evans, Andreas, Schneider, Anke, Torp, Beate, Iwig, Boris, Perras, Christian, Marx, Christof, Blaser, Claudia, Emde, Detlef, Krieter, Dunja, Fuchs, Ellen, Irmler, Eva, Platen, Hans, Schmidt-Gürtler, Hendrik, Schlee, Holger, Naujoks, Ines, Schlee, Sabine, Cäsar, Joachim, Beige, Jochen, Röthele, Justyna, Mazur, Kai, Hahn, Katja, Blouin, Katrin, Neumeier, Kirsten, Anding-Rost, Lothar, Schramm, Monika, Hopf, Nadja, Wuttke, Nikolaus, Frischmuth, Pawlos, Ichtiaris, Petra, Kirste, Petra, Schulz, Sabine, Aign, Sandra, Biribauer, Sherin, Manan, Silke, Röser, Stefan, Heidenreich, Stephanie, Palm, Susanne, Schwedler, Sylke, Delrieux, Sylvia, Renker, Sylvia, Schättel, Theresa, Stephan, Thomas, Schmiedeke, Thomas, Weinreich, Til, Leimbach, Torsten, Stövesand, Udo, Bahner, Wolfgang, Seeger, Cupisti, Adamasco, Adelia, Sagliocca, Alberto, Ferraro, Alessandra, Mele, Alessandro, Naticchia, Alex, Còsaro, Andrea, Ranghino, Andrea, Stucchi, Angelo, Pignataro, Antonella De Blasio, Antonello, Pani, Aris, Tsalouichos, Bellasi, Antonio, Biagio Raffaele Di Iorio, Butti, Alessandra, Cataldo, Abaterusso, Chiara, Somma, Claudia, D'Alessandro, Claudia, Zullo, Claudio, Pozzi, Daniela, Bergamo, Daniele, Ciurlino, Daria, Motta, Domenico, Russo, Enrico, Favaro, Federica, Vigotti, Ferruccio, Ansali, Ferruccio, Conte, Francesca, Cianciotta, Francesca, Giacchino, Francesco, Cappellaio, Francesco, Pizzarelli, Gaetano, Greco, Giada, Bigatti, Giancarlo, Marinangeli, Gianfranca, Cabiddu, Giordano, Fumagalli, Giorgia, Caloro, Giorgina, Piccoli, Giovanbattista, Capasso, Giovanni, Gambaro, Giuliana, Tognarelli, Giuseppe, Bonforte, Giuseppe, Conte, Giuseppe, Toscano, Goffredo Del Rosso, Irene, Capizzi, Ivano, Baragetti, Lamberto, Oldrizzi, Loreto, Gesualdo, Luigi, Biancone, Manuela, Magnano, Marco, Ricardi, Maria Di Bari, Maria, Laudato, Maria Luisa Sirico, Martina, Ferraresi, Michele, Provenzano, Moreno, Malaguti, Nicola, Palmieri, Paola, Murrone, Pietro, Cirillo, Pietro, Dattolo, Pina, Acampora, Rita, Nigro, Roberto, Boero, Roberto, Scarpioni, Rosa, Sicoli, Rosella, Malandra, Silvana, Savoldi, Silvio, Bertoli, Silvio, Borrelli, Stefania, Maxia, Stefano, Maffei, Stefano, Mangano, Teresa, Cicchetti, Tiziana, Rappa, Valentina, Palazzo, Walter De Simone, Anita, Schrander, Bastiaan van Dam, Carl, Siegert, Carlo, Gaillard, Charles, Beerenhout, Cornelis, Verburgh, Cynthia, Janmaat, Ellen, Hoogeveen, Ewout, Hoorn, Friedo, Dekker, Johannes, Boots, Henk, Boom, Jan-Willem, Eijgenraam, Jeroen, Kooman, Joris, Rotmans, Kitty, Jager, Liffert, Vogt, Maarten, Raasveld, Marc, Vervloet, Marjolijn van Buren, Merel van Diepen, Nicholas, Chesnaye, Paul, Leurs, Pauline, Voskamp, Sadie van Esch, Siska, Boorsma, Stefan, Berger, Constantijn, Konings, Zeynep, Aydin, Aleksandra, Musiała, Anna, Szymczak, Ewelina, Olczyk, Hanna, Augustyniak-Bartosik, Ilona, Miśkowiec-Wiśniewska, Jacek, Manitius, Joanna, Pondel, Kamila, Jędrzejak, Katarzyna, Nowańska, Łukasz, Nowak, Magdalena, Durlik, Szyszkowska, Dorota, Teresa, Nieszporek, Zbigniew, Heleniak, Andreas, Jonsson, Björn, Rogland, Carin, Wallquist, Denes, Vargas, Emöke, Dimény, Fredrik, Sundelin, Fredrik, Uhlin, Gunilla, Welander, Isabel Bascaran Hernandez, Knut-Christian, Gröntoft, Maria, Stendahl, Maria Eriksson Svensson, Olof, Heimburger, Pavlos, Kashioulis, Stefan, Melander, Tora, Almquist, Alistair, Woodman, Anna, Mckeever, Asad, Ullah, Barbara, Mclaren, Camille, Harron, Carla, Barrett, Charlotte, O'Toole, Christina, Summersgill, Colin, Geddes, Deborah, Glowski, Deborah, Mcglynn, Dympna, Sands, Fergus, Caskey, Geena, Roy, Gillian, Hirst, Hayley, King, Helen, Mcnally, Houda, Masri-Senghor, Hugh, Murtagh, Hugh, Rayner, Jane, Turner, Joanne, Wilcox, Jocelyn, Berdeprado, Jonathan, Wong, Joyce, Banda, Kirsteen, Jones, Lesley, Haydock, Lily, Wilkinson, Margaret, Carmody, Maria, Weetman, Martin, Joinson, Mary, Dutton, Michael, Matthews, Neal, Morgan, Nina, Bleakley, Paul, Cockwell, Paul, Roderick, Phil, Mason, Philip, Kalra, Rincy, Sajith, Sally, Chapman, Santee, Navjee, Sarah, Crosbie, Sharon, Brown, Sheila, Tickle, Suresh, Mathavakkannan, and Ying, Kuan

Subjects
3-carboxy-4-methyl-5-propyl-2-furanpropionate, CKD, fish intake, kidney replacement therapy, mortality, red meat, trimethylamine N-oxide, uremic toxins
Published
2022

6. The low-protein diet for chronic kidney disease: 8 years of clinical experience in a nephrology ward

Author

Elena Alberghini, Ilaria De Simone, Claudio Pozzi, Chiara Capitanio, Ivano Baragetti, Veronica Terraneo, Vicenzo La Milia, Laura Buzzi, Silvia Furiani, Maria Carmen Luise, Gaia Santagostino, Francesca Ferrario, and Cecilia Biazzi

Subjects
Nephrology, medicine.medical_specialty, medicine.medical_treatment, 030232 urology & nephrology, Renal function, 030204 cardiovascular system & hematology, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Low-protein diet, Internal medicine, medicine, Dialysis, Transplantation, business.industry, low-protein diet, Original Articles, medicine.disease, Confidence interval, dialysis, severe CKD, Hemodialysis, business, Body mass index, Kidney disease
Abstract

BackgroundGuidelines indicate that a low-protein diet (LPD) delays dialysis in severe chronic kidney disease (CKD). We assessed the value of these guidelines by performing a retrospective analysis in our renal clinical practice.MethodsThe analysis was performed from 1 January 2010 to 31 March 2018 in 299 CKD Stage 4 patients followed for 70 months in collaboration with a skilled nutritionist. The patients included 43 patients on a controlled protein diet (CPD) of 0.8 g/kg/day [estimated glomerular filtration rate (eGFR) 20–30 mL/min/1.73 m2 body surface (b.s.)], 171 patients on an LPD of 0.6 g/kg/day and 85 patients on an unrestricted protein diet (UPD) who were not followed by our nutritionist (LPD and UPD, eGFR ResultseGFR was higher in CPD patients than in UPD and LPD patients (21.9 ± 7.4 mL/min/1.73 m2 versus 17.6 ± 8.00 mL/min/1.73 m2 and 17.1 ± 7.5 mL/min/1.73 m2; P = 0.008). The real daily protein intake was higher in UPD patients than in LPD and CDP patients (0.80 ± 0.1 g/kg/day versus 0.6 ± 0.2 and 0.63 ± 0.2 g/kg/day; P = 0.01). Body mass index (BMI) was stable in the LPD and CPD groups but decreased from 28.5 ± 4.52 to 25.4 ± 3.94 kg/m2 in the UPD group (P ConclusionsAn LPD recommended by nephrologists in conjunction with skilled dietitians delays dialysis and preserves nutritional status in severe CKD.

Published
2019
Full Text
View/download PDF

7. Trombolisi accelerata microsonica: trattamento innovativo della trombosi di una fistola artero-venosa nativa

Author

Laura Buzzi, Elena Alberghini, Francesca Ferrario, Ivano Baragetti, Gaia Santagostino, Silvia Furiani, Enzo Corghi, Cristina Sarcina, Veronica Terraneo, Francesco Rastelli, Maria Cristina Gambirasio, Giuseppe Bacchini, and Claudio Pozzi

Subjects
Trombolisi, FAV, Dialisi, Ultrasuoni, Internal medicine, RC31-1245, Diseases of the genitourinary system. Urology, RC870-923
Abstract

Il trattamento della trombosi della FAV con vasi nativi, che è la causa più frequente della perdita dell'accesso vascolare, può avvalersi di diverse tecniche: trombolisi farmacologica, trombolisi meccanica e trombectomia chirurgica, cui associare la correzione della stenosi che ha provocato la trombosi. La trombolisi diretta mediante cateterismo endovascolare con o senza tombolisi meccanica sta diventando la terapia di prima scelta. La tombolisi accelerata microsonica (TAM) è un trattamento endovascolare innovativo: grazie all'emissione di ultrasuoni da parte di un catetere multilume che rilascia contemporaneamente il fibrinolitico all'interno del trombo, la TAM è più rapida, più efficace e più sicura rispetto alla sola fibrinolisi e, rispetto alla tombolisi meccanica, non è traumatica, ha un bassissimo rischio di embolizzazione e non provoca emolisi. La TAM, da poco impiegata nelle trombosi acute arteriose e venose profonde e nelle tromboembolie polmonari massive, è stata da noi utilizzata per la prima volta per trattare la trombosi acuta di una FAV radio-cefalica estesa all'intero circolo venoso superficiale dell'avambraccio per una lunghezza complessiva di 20 cm. La TAM è risultata una tecnica semplice, ben tollerata e mini-invasiva che ha reso utilizzabile la FAV subito dopo la tombolisi. Dopo 15 mesi, la FAV è pervia e funziona bene.

Published
2013
Full Text
View/download PDF

8. SARS-CoV-2 and Hemodialysis: diffusion and mortality in patients and health care team. Reflections from the Lombardy experience

Author

Giuseppe, Rombolà, Marco, Heidempergher, Marina, Cornacchiari, Ivano, Baragetti, Federico, Pieruzzi, Rombolà, G, Heidempergher, M, Cornacchiari, M, Baragetti, I, and Pieruzzi, F

Subjects
medicine.medical_specialty, 2019-20 coronavirus outbreak, medicine.medical_treatment, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Comorbidity, Renal Dialysis, Pandemic, Epidemiology, Health care, medicine, Humans, In patient, Pandemics, SARS‑CoV‑2, Patient Care Team, business.industry, SARS-CoV-2, COVID-19, medicine.disease, Survival Rate, Editorial, Italy, Nephrology, Hemodialysis, Emergency medicine, Kidney Failure, Chronic, business
Published
2021

9. 374 T/A RAGE polymorphism is associated with chronic kidney disease progression in subjects affected by nephrocardiovascular disease.

Author

Ivano Baragetti, Giuseppe Danilo Norata, Cristina Sarcina, Andrea Baragetti, Francesco Rastelli, Laura Buzzi, Liliana Grigore, Katia Garlaschelli, Claudio Pozzi, and Alberico Luigi Catapano

Subjects
Medicine, Science
Abstract

Chronic kidney disease (CKD) patients present elevated advanced glycation end products (AGEs) blood levels. AGEs promote inflammation through binding to their receptor (RAGE), located on the membrane of mesangial cells, endothelial cells and macrophages. Several genetic polymorphisms influence RAGE transcription, expression and activity, including the substitution of a thymine with an adenine (T/A) in the position -374 of the gene promoter of RAGE. Our study investigates the role of -374 T/A RAGE polymorphism in CKD progression in subjects affected by nephrocardiovascular disease.174 patients (119 males (68.4%) mean age 67.2±0.88 years; 55 females (31.6%): mean age 65.4±1.50 years) affected by mild to moderate nephrocardiovascular CKD were studied. Each subject was prospectively followed for 84 months, every 6-9 months. The primary endpoint of the study was a rise of serum creatinine concentrations above 50% of basal values or end stage renal disease.Carriers of the A/A and T/A genotype presented higher plasma levels of interleukin 6 (A/A 29.5±15.83; T/A 30.0±7.89, vs T/T 12.3±5.04 p = 0.01 for both) and Macrophages chemoattractant protein 1 (A/A 347.1±39.87; T/A 411.8±48.41, vs T/T 293.5±36.20, p = 0.04 for both) than T/T subjects. Carriers of the A allele presented a faster CKD progression than wild type patients (Log-Rank test: Chi square = 6.84, p = 0,03). Cox regression showed that -374 T/A RAGE polymorphism (p = 0.037), albuminuria (p = 0.01) and LDL cholesterol (p = 0.038) were directly associated with CKD progression. HDL cholesterol (p = 0.022) and BMI (p = 0.04) were inversely related to it. No relationship was found between circulating RAGE and renal function decline.-374 T/A RAGE polymorphism could be associated with CKD progression and inflammation. Further studies should confirm this finding and address whether inhibiting RAGE downstream signalling would be beneficial for CKD progression.

Published
2013
Full Text
View/download PDF

10. [Utility of computerized vascular access monitoring: a pilot study]

Author

Giovanni, Grasso, Laura, Buzzi, Maria Cristina, Gambirasio, Paolo, Fabbrini, and Ivano, Baragetti

Subjects
Arteriovenous Shunt, Surgical, Renal Dialysis, Humans, Pilot Projects, Thrombosis, Vascular Patency, Retrospective Studies
Abstract

The surveillance of a vascular access (VA) is of primary importance for its outcome and for the patients' survival. However, there is still confusion about its usefulness, who should make it (physician or nurse) and when, and what is the best functional test to use. This retrospective analysis reports our experience of VA monitoring; it is based on the collaboration between concept doctors and nurses and on parameters integration, realized with the help of a software for vascular access monitoring (SMAV) designed by us. The analysis confronts the data gathered on a group of 100 patients, 13 months before the adoption of the SMAV, and another 100 patients, 19 months after. Of these patients, 13 belonged to both groups and were "controls of themselves". The number of thrombosis and angioplasties (PTA) plummeted in the 19 months in which the SMAV was used, from 10 (10%; 0.008 thrombosis/patient month) to 1 (1%; 0.0005 thrombosis/patient month) (p0.01) and from 49 (49%; 0.037 PTA/patient month) to 27 (27%; 0.014PTA/patient month) (p0.05) respectively. In the 13 control patients, a reduction of 70% in the number of PTA (from 26 to 8) was observed. SMAV allowed us to integrate the many functional parameters, making it easy to share information, encouraging teamwork, strengthening professional skills, and favouring the best management of AVs. The result was a reduction in thrombotic events and, surprisingly, a reduction of the need for PTA, most likely thanks to the higher level of attention in the evaluation and puncture of AV.

Published
2020

11. P0366SAFETY OF STEROID THERAPY IN IGA NEPHROPATHY: THE CLINICAL EXPERIENCE OF 48 NEPHROLOGY UNITS IN ITALY

Author

Cristina Sarcina, Ivano Baragetti, Francesca Ferrario, Federico Alberici, Domenico Giannese, Elena Mancini, Claudio Pozzi, Alessandra Pola, Mario Cozzolino, Maria Carmen Luise, Anna Sara Sorrentino, Andrea Amendola, and Cristiana Rollino

Subjects
Nephrology, Transplantation, medicine.medical_specialty, Leukopenia, Proteinuria, business.industry, Odds ratio, medicine.disease, Nephropathy, Sepsis, Steroid therapy, Internal medicine, medicine, medicine.symptom, Adverse effect, business
Abstract

Background and Aims Steroid therapy is efficient in inducing remission of IgA nephropathy (IgAN) and preventing end stage renal disease (ESRD) but there are concerns about their safety. The TESTING trial in particular has been stopped early because of a higher incidence of side effects than conservative treatment thus inducing a conservative therapy with RAAS (renin angiotensin antagonist system) blockers. The aim of this analysis was to evaluate the incidence of adverse events (AE) in a retrospective observational trial on the real clinical practice. Method We evaluated 1209 patients (pz) with IgAN coming from 48 Italian centers: 285 pz in RAAS blockers alone, 732 treated for 6 months with steroid and 192 with a combination of steroid and other immunosuppressants (also with RAAS blockers). The analysis was limited to the 6 months of therapy. Results The basal characteristics of the 3 groups are shown in the table below. The figure shows the frequencies of 69 adverse events related with immunosuppression: the most frequent were infections (23, 2.73% of all patients, 34.3% of all AE), impaired glycemic control (11, 0.91% of patients, 16% of all AE), severe hypertension (6, 8.7% of all AE) and leukopenia (9, 0.80% of patients, 13% of all AE). Infections were observed in 16 (2.19%) pz in steroid therapy and 7 (3.65%) pz in steroid+immunosoppressive treatment. Liver toxicity and and gastrointestinal AE were observed almost in pz receiving steroid+ immunosuppressants [1(0.14%) and 2 (1.04%) pz, respectively]. 7 pz in steroid therapy (0.96%) and 2 in steroid+ immunosuppressants experienced an impaired glycemic control. All the 9 cases of leucopenia were registered in pz in steroid+ immunosuppressants (4.69%). A slightly higher incidence of allergies was observed in the RAAS blocker group (20 cases, 0.7%). The higher rates of infections and leucopenia were observed in pz above 70 years of age (6.12%,p Conclusion the incidence of EA in our observational study is lower than that observed in the TESTING and STOP trials (5.71% vs 14.7% and 40%, respectively). The most frequent AE were almost observed in oldest subjects with impaired renal function on steroid+other immunosuppressants. Though this trial is not randomized nor controlled (RC), it considers a large cohort of pz coming from the real clinical practice of the Italian Nephrology Units and demonstrates that the significantly lower incidence of steroid related AE than that observed in some RC trials doesn’t justify the abstention from steroids in IgAN at risk of progression. Much more attention should be paid in elderly pts with severe renal dysfunction with a closer follow-up, dose adjustments and antibiotic prophilaxis.

Published
2020
Full Text
View/download PDF

12. MO040LONG-TERM FOLLOW-UP OF IGA NEPHROPATHY PATIENTS AT HIGH RISK OF PROGRESSION ACCORDING TO THE THERAPEUTIC APPROACH EMPLOYED: A MULTICENTER RETROSPECTIVE STUDY OF 947 PATIENTS

Author

Grazia Di Cesare, Serena Ponti, Lucia Del Vecchio, Antonello Pani, Francesca Viazzi, Ivano Baragetti, Carlo Manno, Claudio Pozzi, Francesca Ferrario, Federico Alberici, Chiara Salviani, and Giuliano Boscutti

Subjects
Oncology, Immunoglobulin A, Transplantation, medicine.medical_specialty, Proteinuria, Angiotensin Receptor Antagonists, biology, Surrogate endpoint, business.industry, Retrospective cohort study, medicine.disease, Nephropathy, Therapeutic approach, Nephrology, Internal medicine, medicine, biology.protein, medicine.symptom, Adverse effect, business
Abstract

Background and Aims IgA-nephropathy (IgA-N) is a frequent cause of CKD and ESRD. The optimal therapeutic approach and the role of glucocorticoids and immunosuppression is still debated. Aim of this study was to perform a survey across several Italian centers focusing on the long-term outcome of patients with IgA-N at high risk of progression stratified according to the therapeutic approach employed. Method All the consecutive patients affected by biopsy proven IgA-N, proteinuria >1g/day and a follow-up longer than 24 months have been collected across 48 centers. The population has been divided in three groups according to the therapeutic approach: group-1 received ACEi or ARBs alone, group-2 a six months course of glucocorticoids while group-3 glucocorticoids and immunosuppressive drugs. Primary endpoints have been ESRD free-survival, halving of the eGFR free-survival and rate of non-responders (NR, proteinuria >1 g/day). Secondary endpoints have been assessment of the prognostic role of the time average proteinuria (TAP) as well as of the time average slope of proteinuria (TASP) and rate of severe adverse events (SAEs). Results 947 patients have been included and followed for a median time of 60 months (IQR 24-96). Baseline eGFR and proteinuria in the three groups have been respectively 68.1 (95%CI 63.9-72.4)-67.8 (95%CI 65.3-70.3)-63.3 (95%CI 58.5-68.1) ml/min/1.73m2 (p=0.191) and 2.38 (95%CI 2-2.77)-2.65 (95%CI 2.49-2.82)-3.26 (95%CI 2.89-3.64) g/day (p ESRD free-survival has been longer in the group-2 (p=0.004) (figure, panel A); at subgroup analysis this was restricted to the patients with a eGFR The proportion of NR has been significantly lower in group-2 compared to group-1 throughout the first 36 months of follow-up (figure, panel D); of note being NR during the first 36 months increased the risk of developing ESRD during the follow-up (OR 4 95%CI 2.2-7.3, p The rate of patients experiencing SAEs during the first 6 months of therapy in the three groups has been respectively 2%, 7% and 16%; of these withdrawn of the therapeutic approach employed has been necessary in 67%, 21% and 48%. During the whole follow-up the number of SAEs per 100 patients/years has been respectively 1.9-2.7 and 2.5 in the 3 groups. Conclusion In this large multicenter retrospective survey, the use of glucocorticoids in patients with IgA-N at high risk of progression has been associated to longer ESRD free-survival, longer time to the halving of the eGFR in the subgroup with eGFR

Published
2020
Full Text
View/download PDF

13. New agents to reduce cholesterol levels: implications for nephrologists

Author

Lucia Del Vecchio, Francesco Locatelli, and Ivano Baragetti

Subjects
Population, 030232 urology & nephrology, 030204 cardiovascular system & hematology, Pharmacology, Nephrologists, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Ezetimibe, medicine, Humans, education, Alirocumab, Transplantation, education.field_of_study, Cholesterol, business.industry, Anticholesteremic Agents, PCSK9, PCSK9 Inhibitors, medicine.disease, Evolocumab, chemistry, Cardiovascular Diseases, Nephrology, Kexin, Kidney Diseases, business, Kidney disease, medicine.drug
Abstract

Statins and ezetimibe effectively reduce the burden of cardiovascular (CV) disease in patients with chronic kidney disease (CKD). Unfortunately, many subjects still die or have CV events despite cholesterol-lowering therapy. This is particularly true in patients with more advanced CKD. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that induces the degradation of the low-density lipoprotein receptor by targeting it for lysosomal destruction. Its inhibition causes a dramatic fall in cholesterol levels on top of maximized statin therapy. This goal is obtained with different therapeutic approaches, spanning from monoclonal antibodies to non sense oligonucleotides and silencing RNA (siRNA). Two human, monoclonal antibodies are approved for clinical use; they are still very expensive. Both agents significantly lower cholesterol levels. Evolocumab and alirocumab reduce significantly the risk for CV disease without relevant safety issues. Inclisiran is an siRNA molecule that produces PCSK9-specific RNA silencing. Data from a Phase II study showed significant cholesterol-lowering efficacy. The experience accumulated so far is limited in the CKD population. PCSK9 inhibition also has the potential to reduce the burden of CV in this subset by obtaining a much greater decrease in serum cholesterol compared with statin therapy or ezetimibe. Doubts exist that this approach will improve the outcome of dialysis patients, in whom vascular calcifications predominate.

Published
2019
Full Text
View/download PDF

14. Changes in Proteinuria and Side Effects of Corticosteroids Alone or in Combination with Azathioprine at Different Stages of IgA Nephropathy

Author

Laura Buzzi, Elena Alberghini, Lucia Del Vecchio, Cristina Sarcina, Ivano Baragetti, Antonello Pani, Claudio Pozzi, Carmine Tinelli, Patrizia Scaini, Francesca Ferrario, and Annalisa De Silvestri

Subjects
Adult, Male, medicine.medical_specialty, Epidemiology, 030232 urology & nephrology, Azathioprine, 030204 cardiovascular system & hematology, Critical Care and Intensive Care Medicine, Gastroenterology, Nephropathy, law.invention, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Adrenal Cortex Hormones, Interquartile range, law, Internal medicine, medicine, Humans, Prospective cohort study, Randomized Controlled Trials as Topic, Transplantation, Proteinuria, business.industry, Repeated measures design, Glomerulonephritis, IGA, Original Articles, Middle Aged, medicine.disease, Nephrology, Supportive psychotherapy, Drug Therapy, Combination, Female, Erratum, medicine.symptom, business, Immunosuppressive Agents, Follow-Up Studies, Glomerular Filtration Rate, medicine.drug
Abstract

Time-average proteinuria (TAp) is the strongest predictor of renal survival in IgA nephropathy (IgAN). Little is known about the utility and safety of corticosteroids (CS) to obtain TAp1 g/d in patients with advanced IgAN. This study sought to evaluate TAp at different degree of baseline renal function and histologic severity during CS use and to investigate treatment safety.We performed one-stage individual-patient data meta-analysis among 325 patients with IgAN enrolled in three prospective, randomized clinical trials. Patients were divided into three groups according to treatment: no treatment (NT; supportive therapy), CS, and CS plus azathioprine (CS+A). Associations of TAp with histologic grading, treatment, and eGFR at baseline were performed with linear regression models for repeated measures. The median follow-up duration was 66.6 months (range, 12-144 months).In the first 6 months, proteinuria did not change in the NT group and decreased substantially in the other groups(CS: from a mean±SD of 2.20±1.0 to 0.8 [interquartile range, 0.4-1.2] g/d; CS+A: from 2.876±2.1 to 1.0 [interquartile range, 0.5-1.7] g/d), independent of the degree of histologic damage and baseline eGFR. The percentage of patients who maintained TAp1 g/d was 30.2% in the NT, 67.3% in the CS, and 66.6% in the CS+A group. Thirty-four patients experienced adverse events: none in the NT, 11 (6.4%) in the CS, and 23 (20.7%) in the CS+A group. The risk of developing adverse events increased with decreasing levels of eGFR (from 2.3% to 15.4%). The addition of azathioprine to CS further increased the percentage of patients with adverse events (16.8% versus 5.7% in study 2 and 30.0% versus 15.4% in study 3; overall P0.001).In patients with IgAN, CS can reduce proteinuria and increase the possibility of maintaining TAp1 g/d, regardless of the stage of CKD and the histologic damage. The risk of major adverse events is low in patients with normal renal function but increases in those with impaired renal function and with the addition of azathioprine.

Published
2016
Full Text
View/download PDF

15. Low Plasma Lecithin: Cholesterol Acyltransferase (LCAT) Concentration Predicts Chronic Kidney Disease

Author

Andrea Baragetti, Liliana Grigore, Alberico L. Catapano, Ivano Baragetti, Laura Calabresi, Fabio Pellegatta, Alice Ossoli, Sara Simonelli, Arianna Strazzella, and Giuseppe Danilo Norata

Subjects
high-density lipoproteins, medicine.medical_specialty, food.ingredient, lecithin:cholesterol acyltransferase, Population, Sterol O-acyltransferase, lcsh:Medicine, Renal function, 030204 cardiovascular system & hematology, urologic and male genital diseases, Lecithin, Article, 03 medical and health sciences, Basal (phylogenetics), 0302 clinical medicine, food, Internal medicine, medicine, education, 030304 developmental biology, 0303 health sciences, education.field_of_study, business.industry, lcsh:R, Hazard ratio, General Medicine, medicine.disease, Endocrinology, Cohort, lipids (amino acids, peptides, and proteins), business, chronic kidney disease, Kidney disease
Abstract

Low high-density lipoprotein-cholesterol (HDL-c) is the most remarkable lipid trait both in mild-to-moderate chronic kidney disease (CKD) patients as well as in advanced renal disease stages, and we have previously shown that reduced lecithin:cholesterol acyltransferase (LCAT) concentration is a major determinant of the low HDL phenotype. In the present study, we test the hypothesis that reduced LCAT concentration in CKD contributes to the progression of renal damage. The study includes two cohorts of subjects selected from the PLIC study: a cohort of 164 patients with CKD (NefroPLIC cohort) and a cohort of 164 subjects selected from the PLIC participants with a basal estimated glomerular filtration rate (eGFR) &gt, 60 mL/min/1.73 m2 (PLIC cohort). When the NefroPLIC patients were categorized according to the LCAT concentration, patients in the 1st tertile showed the highest event rate at follow-up with an event hazard ratio significantly higher compared to the 3rd LCAT tertile. Moreover, in the PLIC cohort, subjects in the 1st LCAT tertile showed a significantly faster impairment of kidney function compared to subjects in the 3rd LCAT tertile. Serum from subjects in the 1st LCAT tertile promoted a higher reactive oxygen species (ROS) production in renal cells compared to serum from subjects in the third LCAT tertile, and this effect was contrasted by pre-incubation with recombinant human LCAT (rhLCAT). The present study shows that reduced plasma LCAT concentration predicts CKD progression over time in patients with renal dysfunction, and, even more striking, it predicts the impairment of kidney function in the general population.

Published
2020
Full Text
View/download PDF

16. Sodium removal and plasma tonicity balance are not different in hemodialysis and hemodiafiltration using high-flux membranes

Author

Francesca Ferrario, Chiara Ravasi, Giuseppe Pontoriero, Vincenzo La Milia, Fabio Carfagna, Elena Alberghini, Ivano Baragetti, Silvia Furiani, Gaia Santagostino Barbone, and Laura Buzzi

Subjects
Male, medicine.medical_specialty, Sodium, medicine.medical_treatment, 030232 urology & nephrology, Urology, chemistry.chemical_element, Hemodiafiltration, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Renal Dialysis, Diabetes mellitus, Extracellular, Medicine, Humans, Prospective Studies, Balance (ability), integumentary system, business.industry, medicine.disease, Membrane, Blood pressure, Treatment Outcome, chemistry, Nephrology, Tonicity, Kidney Failure, Chronic, Female, Hemodialysis, business, Follow-Up Studies
Abstract

The clinical benefits of on-line hemodiafiltration (HDF) versus high-flux membranes hemodialysis (hf-HD) are still debated. In fact, although a superiority of one treatment over the other, especially in terms of mortality, did not emerge from the analysis of clinical trials, improved intradialytic vascular stability and cardiovascular mortality have been observed in patients undergoing HDF rather than hf-HD; the lower removal of sodium (Na+) during HDF seems to play a major role. The plasma concentration of Na+ is the major determinant of plasma tonicity, which, by determining the flow of water between the intracellular and the extracellular compartment, contributes to the vascular refilling process and the maintenance of blood pressure during the hemodialysis treatment. Plasma tonicity also depends on plasma glucose concentration, especially in patients with diabetes mellitus with hyperglycaemia at the start of hemodialysis treatment. We evaluated the removal of Na+ and plasma tonicity balance during a 2-week period by performing 2–3 consecutive sessions of hf-HD followed by 2–3 consecutive sessions of HDF, or vice versa, in 47 patients (40% diabetics) on chronic hemodialysis. Identical parameters were used in all dialytic sessions. Na+ removal per session was − 224 ± 144 mmol and − 219 ± 152 mmol, respectively, in hf-HD and in HDF (p = 0.79). The plasma tonicity balance per session was − 575 ± 310 mOsm and − 563 ± 328 mOsm, respectively, in hf-HD and in HDF (p = 0.75). The removal of Na+ and plasma tonicity balance did not differ between hf-HD and HDF. This observation suggests that factors other than those assessed in our study might explain the improved cardiovascular stability reported in HDF.

Published
2018

17. Targeting Immunity in End-Stage Renal Disease

Author

Ivano Baragetti, Paolo Fiorina, and Basset El Essawy

Subjects
medicine.medical_specialty, medicine.medical_treatment, 030232 urology & nephrology, MEDLINE, Anti-Inflammatory Agents, Disease, 030204 cardiovascular system & hematology, urologic and male genital diseases, Antioxidants, End stage renal disease, 03 medical and health sciences, 0302 clinical medicine, Immunity, Renal Dialysis, Risk Factors, Diabetes mellitus, medicine, Humans, Intensive care medicine, Dialysis, Inflammation, Clinical Trials as Topic, business.industry, Incidence (epidemiology), Incidence, Complement System Proteins, medicine.disease, female genital diseases and pregnancy complications, Oxidative Stress, C-Reactive Protein, Complement Inactivating Agents, Nephrology, Cardiovascular Diseases, Cytokines, Kidney Failure, Chronic, business
Abstract

Background: Despite the stable incidence of end-stage renal disease (ESRD), it continues to be associated with an unacceptably high cardiovascular risk. Summary: ESRD is characterized by enhanced oxidative stress and severe inflammation, which boost cardiovascular risk, thus increasing cardiovascular-associated mortality rate. While substantial effort has been made in the technological innovation of dialytic techniques, few significant advances have been made to reduce inflammation in patients with ESRD. Indeed, this contrasts with the extensive scientific breakthroughs made in the basic field of science in targeting inflammation. There is thus a pressing need for clinical trials to test the effect of reducing inflammation in patients with ESRD. Here, we will revisit the negative effect of ESRD on inflammation and explore the impact of enhanced inflammation on cardiovascular outcomes and survival in patients with ESRD. Finally, we will discuss the need for clinical trials that target inflammation in ESRD, as well as weigh potential disadvantages and offer novel innovative approaches. Key Message: We will try to understand why the issue of inflammation has not been successfully addressed thus far in patients with ESRD, while at the same time weighing the potential disadvantages and offering novel innovative approaches for targeting inflammation in patients with ESRD.

Published
2017

18. Ultrasound-accelerated thrombolysis: an innovative technique to treat native arteriovenous fistula acute thrombosis

Author

Claudio Pozzi, Francesco Rastelli, Silvia Furiani, Maria Cristina Gambirasio, Francesca Ferrario, Enzo Corghi, Laura Buzzi, Elena Alberghini, Cristina Sarcina, Ivano Baragetti, Giuseppe Bacchini, Veronica Terraneo, and Gaia Santagostino

Subjects
medicine.medical_specialty, business.industry, medicine.medical_treatment, Ultrasound, Arteriovenous fistula, General Medicine, Thrombolysis, medicine.disease, Internal medicine, medicine, Cardiology, Acute thrombosis, Radiology, business
Published
2013
Full Text
View/download PDF

19. Plasma adiponectin levels in chronic kidney disease patients: Relation with molecular inflammatory profile and metabolic status

Author

Gherardo Buccianti, Arthur F. Stucchi, G. Piloni, Sara Raselli, Ivano Baragetti, Katia Garlaschelli, Alberico L. Catapano, Giuseppe Danilo Norata, and S. Vettoretti

Subjects
Adult, Male, Aging, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Medicine (miscellaneous), Renal function, Cohort Studies, Young Adult, chemistry.chemical_compound, Internal medicine, Humans, Medicine, Renal Insufficiency, Chronic, Dialysis, Aged, Aged, 80 and over, Inflammation, Metabolic Syndrome, Creatinine, Nutrition and Dietetics, Adiponectin, business.industry, Gene Expression Profiling, Cholesterol, HDL, Middle Aged, medicine.disease, Endocrinology, Intima-media thickness, chemistry, Cardiovascular Diseases, Female, Resistin, Metabolic syndrome, Cardiology and Cardiovascular Medicine, business, Biomarkers, Glomerular Filtration Rate, Kidney disease
Abstract

Background and Aim Adiponectin (ADPN) exerts anti-inflammatory and cardio protective effects and is associated with decreased cardiovascular risk, however its role in patients with chronic kidney disease is unclear. Methods and Results We investigated the correlation between plasma ADPN levels, the progression of CVD and CKD and the inflammatory gene expression profile of peripheral blood mononuclear cells in patients from the NephroPLIC study (a prospective study aimed at addressing the progression of cardiovascular damage in relation to kidney dysfunction). Plasma ADPN levels were directly correlated with age, HDL-C and creatinine, and inversely with BMI, triglycerides and glomerular filtration rate (GFR). Multiple regression analysis identified plasma creatinine and HDL as the independent factors associated with ADPN plasma levels. In peripheral blood mononuclear cells (PBMC), the mRNA expression of MCP-1, CD40, Cox-2, TLR4, PAI-1, TNF alpha, resistin and RAGE was up-regulated in the group with higher GFR and higher ADPN plasma levels compared to that with low GFR and ADPN plasma levels. Patients with similar GFR values showed no differences in the gene expression profile of PBMC although ADPN levels were associated with decreased CRP and IL-6 plasma levels and decreased IMT and heart left ventricular mass. Conclusion In CKD patients who are not in dialysis ADPN plasma levels are associated with a reduced renal excretory function, but correlate inversely with the determinants of the metabolic syndrome such as glucose, triglycerides and BMI, and directly with HDL. Furthermore, in patients with a similar degree of renal impairment, ADPN plasma levels are associated with a better cardiometabolic profile, despite no significant difference being observed in the gene expression pattern of PBMC.

Published
2010
Full Text
View/download PDF

20. In Subjects Affected by Chronic Kidney Disease and Type II Diabetes Mellitus Urinary Albumin Excretion is Predictive of Peripheral Endothelial Dysfunction Independently of Systemic Inflammatory Status

Author

Giuseppe Danilo Norata, Arthur F. Stucchi, Alberico L. Catapano, Gherardo Buccianti, V. Terraneo, Ivano Baragetti, S. Vettoretti, and Sara Raselli

Subjects
medicine.medical_specialty, business.industry, medicine.disease, Pharmacotherapy, Internal medicine, Internal Medicine, Albuminuria, medicine, Cardiology, medicine.symptom, Cardiology and Cardiovascular Medicine, business, Kidney disease, Subclinical infection
Published
2007
Full Text
View/download PDF

21. Role of Vitamin E-Coated Membrane in Reducing Advanced Glycation End Products in Hemodialysis Patients: A Pilot Study

Author

Silvia Furiani, Gherardo Buccianti, Alberico L. Catapano, Ivano Baragetti, Francesco Galli, Sara Raselli, S. Vettoretti, and F.M. Maggi

Subjects
Glycation End Products, Advanced, Male, Vitamin, medicine.medical_specialty, Brachial Artery, Endothelium, medicine.medical_treatment, Pilot Projects, Arginine, Antioxidants, chemistry.chemical_compound, Renal Dialysis, Glycation, medicine.artery, Internal medicine, medicine, Humans, Vitamin E, Pentosidine, Brachial artery, Homocysteine, Aged, Analysis of Variance, Lysine, Membranes, Artificial, Hematology, General Medicine, Middle Aged, Surgery, Lipoproteins, LDL, Vasodilation, Oxidative Stress, medicine.anatomical_structure, Endocrinology, chemistry, Nephrology, Linear Models, Female, Coated membrane, Endothelium, Vascular, Hemodialysis
Abstract

Introduction: Advanced glycation end products (AGEs) are markers of oxidative stress. Aims: To assess if a vitamin-E-coated dialyzer affects plasma AGE levels and endothelial function in hemodialysis patients. Methods: 16 patients were dialyzed with a synthetic modified cellulose membrane (SMC, n = 8) or a vitamin E-coated dialyzer (n = 8), respectively. At week 32 endothelial function was determined as brachial artery flow-mediated dilatation (FMD). Total AGEs, free pentosidine (FP), protein-bound pentosidine (BP) and autoantibodies against oxidized LDL (ox-LDL-autoantibodies) were assessed at baseline (T0) and at 16, 32, 40 and 42 weeks (T16, T32, T40 and T42). Results: At T16 and T32 FP and BP were lower in vitamin E than in SMC (T 16: 88.7 ± 8.96 vs. 124.2 ± 11.90 pmol/ml plasma; p = 0.04, and 22.9 ± 2.99 vs. 32.8 ± 2.98 pmol/mg proteins; p = 0.04. T32: 78.7 ± 8.54 vs. 123.7 ± 10.15 pmol/ml plasma; p = 0.007, and 19.9 ± 2.0 vs. 33.67 ± 2.41 pmol/mg proteins; p = 0.001). In vitamin E, AGEs were lower at T32, T40 and T42 (946.7 ± 80.91 vs. 1,351.2 ± 179.33 AU/ml, p = 0.05; 986.9 ± 59.63 vs. 1,509.9 ± 154.17 AU/ml, p = 0.013; 890.3 ± 73.70 vs. 1,453.9 ± 153.16 AU/ml, p = 0.009). At T32 AGEs, ox-LDL autoantibodies and FMD were inversely correlated (R = –0.70 p = 0.007 and R = –0.59, p = 0.04, respectively). Conclusions: Vit E-coated membrane reduces plasma AGEs levels and AGEs values are negatively correlated with FMD.

Published
2006
Full Text
View/download PDF

22. 5-methyltetrahydrofolate restores endothelial function in uraemic patients on convective haemodialysis

Author

Cristina Patrosso, Gherardo Buccianti, F.M. Maggi, Ivano Baragetti, Enzo Corghi, Fabrizia Bamonti, Sara Raselli, Cristina Novembrino, and Alberico L. Catapano

Subjects
Male, Heterozygote, medicine.medical_specialty, Hyperhomocysteinemia, Genotype, Homocysteine, Injections, Subcutaneous, Hyperaemia, chemistry.chemical_compound, Renal Dialysis, Internal medicine, medicine.artery, Humans, Medicine, Vitamin B12, Endothelial dysfunction, Brachial artery, Tetrahydrofolates, Ultrasonography, Uremia, Transplantation, business.industry, Homozygote, Middle Aged, medicine.disease, Vasodilation, Vitamin B 12, Endocrinology, chemistry, Nephrology, Injections, Intravenous, Drug Therapy, Combination, Female, Endothelium, Vascular, medicine.symptom, Isosorbide dinitrate, business, medicine.drug
Abstract

BACKGROUND Hyperhomocysteinaemia is an independent risk factor for the development of atherosclerosis. In patients with chronic renal failure, the administration of folic acid or its metabolites reduces but does not normalize plasma homocysteine concentrations. Furthermore, homocysteine induces endothelial dysfunction by an increased inactivation of nitric oxide. METHODS We examined the effect of the active metabolite of folic acid, 5-methyltetrahydrofolate (5-MTHF), 45 mg/week i.v. for 10 weeks, combined during the last 2 weeks with vitamin B12, 500 microg s.c. twice weekly, on homocysteinaemia and endothelial function in 15 patients undergoing convective haemodialysis. Endothelial function was evaluated by B-mode ultrasonography on the brachial artery. Flow-mediated dilation (FMD) was recorded during reactive hyperaemia produced by inflation of a pneumatic tourniquet. Nitroglycerine-mediated dilation (NMD) was recorded after administration of isosorbide dinitrate. Finally, the presence of the thermolabile variant of methyltetrahydrofolate reductase (t-MTHFR) was assessed by genotype analysis. RESULTS Plasma homocysteine concentrations fell by 47% after treatment with 5-MTHF alone and by a further 13.6% after the addition of vitamin B12. The reduction was more marked in homo- and heterozygous patients than in normal genotypes for t-MTHFR. Flow-mediated endothelial vasodilation, measured by ultrasonography of the brachial artery, improved after administration of 5-MTHF (12.52+/- 2.47% vs. 7.03+/-1.65%; P

Published
2002
Full Text
View/download PDF

23. [Assisted peritoneal dialysis]

Author

Elena, Alberghini, Francesco, Rastelli, Raffaella, Di Nardo, Lidia, Rognoni, M Cristina, Gambirasio, Francesca, Ferrario, Silvia, Furiani, Enzo, Corghi, Ivano, Baragetti, Laura, Buzzi, Gaia, Santagostino, Ilaria, De Simone, Anna, Krefta, and Claudio, Pozzi

Subjects
Italy, Allied Health Personnel, Humans, Home Care Services, Peritoneal Dialysis
Abstract

Peritoneal dialysis (PD) has a prevalence in Italy that does not exceed 10% of patients in substitution treatment. Among the barriers, which hinder access to DP, the lack of patient autonomy or family support has great importance. In 2012 in Lombardy, the lack of support has prevented 155 new patients to use DP and has forced 17 to stop it. According to the Italian Census of 2012, made by the Peritoneal Dialysis Study Group, Assisted DP involved the 24.5% of patients in 2010. In these cases, the caregiver was a family member in 80.8% of cases, a carer in 12.4%, a homecare nurse in 2.5% and the retirement home staff in 3.9%. In Italy, several regional Governments have sought to encourage home dialysis with economic contributions to the patient or the family. However, so far, none of these interventions has managed to increase the use of DP. In January 2004, we started a program of Assisted PD, using health worker as caregiver, in agreement with ASL Milano and ICP Milano Hospital. In the first 6 months of activity we treated 4 patients, 3 of them had been treated with hemodialysis. We had no critical cases and patients have welcomed this solution. In addition, the costs related to the Assisted PD are lower in comparison with the costs of the hospital hemodialysis. Considering the reliability of the first results, ASL has decided to raise the economic contribution for this activity, allowing us to increase the number of patients to include in Assisted PD.

Published
2014

24. Reduction of the Homocysteine Plasma Concentration by Intravenously Administered Folinic Acid and Vitamin B12 in Uraemic Patients on Maintenance Haemodialysis

Author

Fabrizia Bamonti Catena, Enzo Corghi, Ivano Baragetti, Cristina Patrosso, Anna Teresa Maiolo, Gherardo Buccianti, Michela De Franceschi, Cristina Novembrino, and Giuliana Lando

Subjects
medicine.medical_specialty, biology, Homocysteine, business.industry, medicine.medical_treatment, fungi, food and beverages, medicine.disease, Uremia, Folinic acid, B vitamins, chemistry.chemical_compound, Endocrinology, chemistry, Nephrology, Internal medicine, Methylenetetrahydrofolate reductase, Blood plasma, medicine, biology.protein, Vitamin B12, Hemodialysis, business, medicine.drug
Abstract

Background: Hyperhomocysteinaemia is an independent cardiovascular risk factor which can induce vascular lesions, thus contributing to the early development of atherosclerosis. Low-dose folic acid supplementation reduces the pretreatment homocysteine plasma levels by 25–35%. Recent studies report that higher intravenous or oral administration of the active form of folic acid reduces the homocysteine plasma concentration by nearly 70%. The reduction could also be influenced by the thermolabile variant of methylenetetrahydrofolate reductase (tMTHFR) and by the dialysis modality. Methods: A cross-sectional clinical study was performed to evaluate the effect of a drug containing folinic acid and vitamin B12 on the plasma homocysteine concentration and whether this variable could also be influenced by the presence of a genetic variant of the methionine pathway and the use of different dialysis modalities. The plasma homocysteine concentration was measured in 55 patients undergoing haemodialysis, 27 of whom have been treated intravenously for megaloblastic anaemia using a drug containing low concentrations of folinic acid and vitamin B12 at the end of each dialysis session for 6 months. The presence of tMTHFR was sought by molecular analysis, and the role of the dialysis modality was also investigated. Results: The patients given the folic acid treatment had lower homocysteine plasma levels than those not so treated. The plasma homocysteine concentration was significantly higher in the tMRHFR homozygotes than in the patients with a normal genotype, significantly lower in the treated than in the untreated homozygotes, and significantly higher in the untreated homozygotes than in the untreated subgroup with a normal genotype. The homocysteine level was also significantly lower in the patients who underwent convective haemodialysis than in those who received standard bicarbonate dialysis. Conclusions: A drug containing low concentrations of folinic acid combined with vitamin B12 using an intermittent intravenous regimen is effective in reducing the homocysteine plasma concentration in uraemic patients. The homocysteine levels seem also to depend on genotype and dialysis modality.

Published
2001
Full Text
View/download PDF

25. Reply

Author

Elena Alberghini, Ivano Baragetti, Silvia Furiani, Alberico L. Catapano, Veronica Terraneo, Sara Raselli, Gherardo Buccianti, Katia Garlaschelli, Andrea Stucchi, and Laura Buzzi

Subjects
Transplantation, medicine.medical_specialty, Hyperhomocysteinemia, Nephrology, business.industry, Internal medicine, medicine, Endothelial dysfunction, medicine.disease, business, Dialysis patients, Gastroenterology
Published
2007
Full Text
View/download PDF

26. Strontium absorption and excretion in normocalciuric subjects: relation tocalcium metabolism

Author

Giuseppe Bianchi, Laura Soldati, Alessandro Rubinacci, Andrea Caumo, GianLuigi Moro, Simona Zerbi, Ivano Baragetti, P. Bellinzoni, A. Centemero, and Giuseppe Vezzoli

Subjects
Calcium metabolism, medicine.medical_specialty, Chemistry, Biochemistry (medical), Clinical Biochemistry, Parathyroid hormone, Urine, Enteral administration, Intestinal absorption, Excretion, Endocrinology, Internal medicine, Renal physiology, Blood plasma, medicine
Abstract

The relationships of Sr intestinal absorption and renal excretion with biohumoral factors regulating Ca metabolism were studied in 47 normocalciuric subjects with Ca kidney stones. Sr concentrations were measured in serum and urine after an oral load of stable Sr (30.2 μmol/kg body wt). Enteral absorption of the ion (9.77 ± 0.438 mmol · L−1 · min, 240 min after Sr administration), expressed as the area under the plasma concentration–time curve (AUC), and renal clearance (CRE) in these subjects during the test (2.80 ± 0.336 mL/min) were not different from values for 27 controls. CRE was not correlated with AUCs. Plasma concentrations of parathyroid hormone (PTH) negatively correlated with AUCs (P

Published
1998
Full Text
View/download PDF

27. High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease

Author

Cristina Sarcina, Ivano Baragetti, Liliana Grigore, Paola Uboldi, Alberico L. Catapano, Giuseppe Danilo Norata, Francesco Rastelli, Christian Pozzi, Andrea Baragetti, and Katia Garlaschelli

Subjects
Male, medicine.medical_specialty, medicine.medical_treatment, Renal function, urologic and male genital diseases, Kidney Function Tests, Gastroenterology, chemistry.chemical_compound, High-density lipoprotein, Predictive Value of Tests, Risk Factors, Internal medicine, Diabetes mellitus, Internal Medicine, medicine, Humans, Prospective Studies, Renal Insufficiency, Chronic, Dialysis, Aged, Creatinine, medicine.diagnostic_test, business.industry, Cholesterol, Cholesterol, HDL, Scavenger Receptors, Class B, medicine.disease, Prognosis, Endocrinology, chemistry, ROC Curve, Case-Control Studies, Disease Progression, Regression Analysis, lipids (amino acids, peptides, and proteins), ATP-Binding Cassette Transporters, Female, business, Lipid profile, Kidney disease
Abstract

Objectives Patients with chronic kidney disease (CKD) often present with reduced plasma HDL cholesterol (HDL-C) levels. Whether this reduction in an epiphenomenon or is involved in disease progression is unclear. The aim of this study was to investigate the relation between HDL-C levels/function and CKD progression in patients with different degrees of disease. Design A total of 176 patients with CKD [glomerular filtration rate (GFR) 50.3 ± 29.1 mL min−1] were recruited and followed for up to 84 months. Lipid profile, metabolic status and kidney function were evaluated at predetermined times. Age-matched control subjects were selected from the PLIC study (n = 453). Scavenger receptor class B member 1 (SR-BI) and ATP-binding cassette transporter A1 (ABCA-1)-dependent efflux of cholesterol were measured in CKD patients and in age-matched control subjects. Results Low HDL-C levels, diabetes and hypertension were associated with reduced GFR. At follow-up, low HDL-C levels were associated with earlier entry in dialysis or doubling of the plasma creatinine level (P = 0.017); HDL-C levels were the only lipid parameter that affected the progression of CKD (hazard ratio 0.951, 95% confidence interval 0.917–0.986, P = 0.007), independently of the presence of diabetes. Only SR-BI-mediated serum cholesterol efflux was significantly reduced in the group of CKD patients with low HDL-C levels compared to the control group. Conclusions CKD patients with low levels of plasma HDL-C have a poor prognosis. HDL functionality is also impaired in renal dysfunction. These data support the relevance of HDL in influencing CKD progression.

Published
2013

28. Effect of Acetate Free Biofiltration on Hyperhomocysteinemia in Uremic Patients: A Cross-sectional Multicenter Study

Author

Silvia Furiani, Enzo Corghi, U Teatini, Ivano Baragetti, Fabrizia Bamonti, A Manfredi, G D'Aloja, Gherardo Buccianti, G Sorgato, and Cristina Patrosso

Subjects
Hyperhomocysteinemia, medicine.medical_specialty, business.industry, 030232 urology & nephrology, Biomedical Engineering, Medicine (miscellaneous), Bioengineering, General Medicine, 030204 cardiovascular system & hematology, medicine.disease, Gastroenterology, Uremia, Biomaterials, 03 medical and health sciences, 0302 clinical medicine, Multicenter study, Internal medicine, Medicine, Acetate-Free Biofiltration, business
Published
2003
Full Text
View/download PDF

29. [The ambiguous concept of predialysis: proposal for a model]

Author

Elena, Alberghini, Maria Cristina, Gambirasio, Cristina, Sarcina, Cecilia, Biazzi, Francesca, Ferrario, Enzo, Corghi, Ivano, Baragetti, Laura, Buzzi, Bianca, Visciano, Veronica, Terraneo, Gaia, Santagostino, and Claudio, Pozzi

Subjects
Patient Care Team, Dietetics, Teaching Materials, Decision Making, Models, Theoretical, Kidney Transplantation, Nurse's Role, Renal Replacement Therapy, Hemodialysis Units, Hospital, Italy, Patient Education as Topic, Nephrology, Terminology as Topic, Humans, Kidney Failure, Chronic, Physician's Role
Abstract

In 2009, 90% of nephrology centers in Lombardy declared to have a ''predialysis'' outpatient department, without, however, specifying its meaning. Research carried out in 2008 among nephrology centers in Piemonte showed how ambiguous this term was. According to the 2007 EDTA-ERA Registry, about 68% of European nephrology centers stated that they had an outpatient department for stage 4-5 CKD patients, but no information was available about the role of patients in the choice of dialysis. It is known that when the predialysis phase is poorly managed, the patient's rehabilitation will be more difficult. Dissatisfaction with dialysis often leads to withdrawal from dialysis, as several registries have shown. For this reason, we created a predialysis course at our center, involving a nephrologist, a nurse, and a dietician. The nephrologist helps the patient choose the most suitable therapeutic strategy, which means that doctor and patient share the responsibility for the treatment choice. The offered options are hemodialysis, peritoneal dialysis, preemptive kidney transplant, and a conservative dietary-pharmacological program. The nurse plans at least 4 meetings: 1) to talk with the patient in order to get to know him or her and his/her family; 2) to provide information about the dialysis procedure and establish the patient's preferences; 3) to clear any doubts about the treatment and deliver a booklet with information about the chosen dialysis procedure; 4) to explain the chosen dialysis procedure; 5) to meet the patient after their preparation for dialysis (vascular access or peritoneal catheter). The dietician manages the dietary programs both for patients who are close to starting dialysis and those on a longlasting conservative program. The predialysis course includes a meeting among all those involved with the patient (nephrologists, nurses, dieticians) to exchange information with the purpose of shared evaluation and decision-making.

Published
2011

30. Improvement of endothelial function in uraemic patients on peritoneal dialysis : a possible role for 5-MTHF administration

Author

Sara Raselli, Andrea Stucchi, Gherardo Buccianti, Silvia Furiani, Veronica Terraneo, Laura Buzzi, Alberico L. Catapano, Katia Garlaschelli, Elena Alberghini, and Ivano Baragetti

Subjects
Male, medicine.medical_specialty, Homocysteine, medicine.medical_treatment, Urology, Sublingual administration, Peritoneal dialysis, chemistry.chemical_compound, Hyperaemia, Folic Acid, medicine.artery, Internal medicine, medicine, Humans, Diabetic Nephropathies, Endothelial dysfunction, Brachial artery, Tetrahydrofolates, Aged, Ultrasonography, Uremia, Transplantation, business.industry, 5-methyltetrahydrofolate, Atherosclerosis, Endothelial function, Plasma homocysteine, Middle Aged, medicine.disease, Vasodilation, Endocrinology, chemistry, Nephrology, Settore BIO/14 - Farmacologia, Kidney Failure, Chronic, Female, Hemodialysis, Endothelium, Vascular, medicine.symptom, business, Peritoneal Dialysis, Kidney disease
Abstract

Background. Hyperhomocysteinaemia is an independent risk factor for the development of atherosclerosis. Furthermore, homocysteine induces endothelial dysfunction by an increased inactivation of nitric oxide. In patients with chronic renal failure, the administration of folic acid or its metabolites reduces but does not normalize plasma homocysteine concentrations. Methods. We examined the effect of oral treatment with 15 mg/daily of 5-methyltetrahydrofolate (5-MTHF) for 12 weeks, on homocysteinaemia and endothelial function in 19 patients undergoing peritoneal dialysis and compared them, for the same period of time, to a control group of patients on peritoneal dialysis. Endothelial function was evaluated by B-mode ultrasonography on the brachial artery. Flow-mediated dilation (FMD) was recorded during reactive hyperaemia produced by the inflation of a pneumatic tourniquet. Nitroglycerine-mediated dilation (NMD) was recorded after sublingual administration of glyceryl trinitrate. Finally, oxidative stress was assessed by evaluating the conjugated dienes plasma levels. Results. Plasma homocysteine concentrations fell by 30% after oral treatment with 5-MTHF. Endothelial function improved significantly after oral 5-MTHF treatment (13.8 � 1.2% vs 11.4 � 1.4%; P < 0.02) while in the control group we observed a worsening of basal values from 12.1 � 2.66% to 8.7 � 2.90% (P < 0.02). The conjugated dienes plasma levels did not change either. Conclusions. Our study demonstrated that 5-MTHF administration improves endothelial dysfunction in patients undergoing peritoneal dialysis. This effect appears to be independent of the reduction in homocysteine plasma levels.

Published
2007

31. Effect of the -420C/G variant of the resistin gene promoter on metabolic syndrome, obesity, myocardial infarction and kidney dysfunction

Author

M. Ongari, Gherardo Buccianti, Maurizio Averna, Davide Noto, G. Tibolla, S. Vettoretti, Alberico L. Catapano, Katia Garlaschelli, Sara Raselli, Angelo B. Cefalù, Giuseppe Danilo Norata, Ivano Baragetti, Liliana Grigore, NORATA, G, ONGARI, M, GARLASCHELLI, K, TIBOLLA, G, GRIGORE, L, RASELLI, S, VETTORETTI, S, BARAGETTI, I, NOTO, D, CEFALU', AB, BUCCIANTI, G, AVERNA, M, and CATAPANO, AL

Subjects
Adult, Male, medicine.medical_specialty, Heart disease, Genotype, Myocardial Infarction, Adipokine, Gene Expression, Single-nucleotide polymorphism, Polymorphism, Single Nucleotide, Cohort Studies, Internal medicine, Internal Medicine, medicine, Humans, Genetic Predisposition to Disease, Resistin, Myocardial infarction, Obesity, RNA, Messenger, Promoter Regions, Genetic, Aged, Metabolic Syndrome, Framingham Risk Score, business.industry, Middle Aged, medicine.disease, Lipids, Endocrinology, Kidney dysfunction, metabolic syndrome, myocardial infarction, PBMC, resistins, SNP, Chronic Disease, Female, Kidney Diseases, Metabolic syndrome, business, Kidney disease
Abstract

Objective. Resistin is an adipokine that has been suggested to be correlated with markers of inflammation and to be predictive of coronary atherosclerosis and type II diabetes in humans. A common single nucleotide polymorphism (SNP) (−420C/G) in the promoter of resistin is associated with increased resistin plasma levels and susceptibility to type II diabetes. The aim of this study was to investigate the association of the -420C/G polymorphism with metabolic syndrome, obesity, myocardial infarction and kidney disease. Design and results. First we studied 1542 subjects from the PLIC study (a population based cohort). GG carriers showed an higher prevalence of obesity and metabolic syndrome as well as increased plasma triglycerides levels, BMI, systolic and diastolic blood pressure and cardiovascular risk according to Framingham algorithm (P

Published
2007

32. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease

Author

Gherardo, Buccianti, Ivano, Baragetti, Fabrizia, Bamonti, Silvia, Furiani, Valentina, Dorighet, and Cristina, Patrosso

Subjects
Male, Cardiovascular Diseases, Renal Dialysis, Risk Factors, Humans, Kidney Failure, Chronic, Regression Analysis, Female, Cholesterol, LDL, Middle Aged, Homocysteine, Survival Analysis, Serum Albumin
Abstract

Hyperhomocysteinemia is considered an independent risk factor for atherosclerosis in patients with normal renal function. Plasma homocysteine (Hcy) is increased in patients with chronic renal failure (CRF) and could be linked to their high cardiovascular (CV) morbidity and mortality. We prospectively studied 77 patients (47 males and 30 females aged 62.85 +/- 1.53 yrs) who had been on maintenance hemodialysis (HD) (4 hr/x3/week) for 65.5 +/- 7.23 months. Patients were followed-up for 44 months. At baseline, blood samples were taken for hemoglobin (Hb), total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, serum calcium, serum phosphates, parathyroid hormone (PTH), Hcy, vitamin B12, serum and erythrocyte folate and methylentetrahydrofolate-reductase (t-MTH-FR) genotype determination. Plasma Hcy levels of patients were divided into four quartiles. The univariate analysis demonstrated a significant relationship between Hcy and diastolic blood pressure (BP) (r=0.45; p=0.003), and both plasma (r=-0.30; p=0.03) and erythrocyte (r=-0.48; p=0.01) folate levels and CV score (r=0.39; p=0.007). Kaplan-Meier analysis showed that the mortality rate due to CV events was statistically significantly higher in the 4th Hcy quartile (68%; 12 patients) vs. the 3rd quartile (12%; two patients), the 2nd quartile (28%; four patients) and the 1st quartile (14%; two patients) (log-rank test p=0.02). Cox's regression analysis for CV survival showed that Hcy was a positive CV mortality predictor (beta=0.02; hazard ratio=1.031; 95% confidence interval (95% CI): 1.013-1.050; p=0.001), while LDL cholesterol and albumin related negatively to CV mortality (LDL cholesterol: beta=-0.02; hazard ratio=0.095; 95% CI: 0.0957-0.0997; p=0.035; albumin: beta=-2.35; hazard ratio=0.097; 95% CI: 0.011-0.847; p=0.026). Our results show that Hcy is a strong independent mortality predictor in HD patients with a 3% increase in mortality for each 1 micromol/L increase in plasma Hcy concentration. This agrees with previous findings confirming the role of Hcy in predicting CV risk factors in uremic patients.

Published
2004

33. Intraperitoneal hydrostatic pressure and flow characteristics of peritoneal catheters in automated peritoneal dialysis

Author

Renzo Scanziani, Beatrice Dozio, Serena Maroni, and Ivano Baragetti

Subjects
Male, medicine.medical_specialty, Time Factors, Body Surface Area, medicine.medical_treatment, Hydrostatic pressure, Urology, Body weight, Peritoneal dialysis, Catheters, Indwelling, Dialysis Solutions, Hydrostatic Pressure, Medicine, Humans, Peritoneal Cavity, Aged, Body surface area, Transplantation, business.industry, Body Weight, Transition time, Middle Aged, Surgery, Automated peritoneal dialysis, Volume (thermodynamics), Nephrology, Positive relationship, Kidney Failure, Chronic, Female, business, Rheology, Peritoneal Dialysis
Abstract

BACKGROUND In automated peritoneal dialysis (APD) one of the most important factors that influence the efficiency of the treatment is the total volume of dialysate infused per session and the dwell time. This study is aimed at examining the relationships between i.p. pressure (IPP), dialysate flow characteristics, and different dialysate fill volumes in order to optimize APD. METHODS We studied 20 patients who received APD, with the standard fill volume (2 l, A), or individualized fill volumes based on the patient's body surface area (2.5 l/BSA/1.73 m, B) or on body weight (40 ml/kg body weight, C). The patient's tolerance to a given fill volume was evaluated by measuring IPP, and catheter flow characteristics were evaluated by an automated machine. RESULTS IPP increased with the increase of the infused volume of dialysate (P < 0.05) and tended towards a positive relationship with the patient's body mass index (BMI: A vs IPP: R = 0.39, P = 0.0019; B vs IPP: R = 0.66, P = 0.0012; C vs IPP R = 0.55, P = 0.009). We also found a relationship between fill volume, BMI and IPP: IPP = 1.0839 + 0.53 (beta) x BMI + 0.211 (beta) x fill volume (R = 0.65; r(2) = 0.40 P < 0.01). The mean IPP with different dialysate fill volumes tended to be related to the volume of dialysate drained at the transition point (R = 0.37; P < 0.05). The pre-transition flow rate/mean IPP ratio tended towards a positive relationship with the volume of dialysate drained at the transition point (R = 0.35, P < 0.05), the transition time (R = 0.34; P < 0.05) and a negative one with the transition volume (R = -0.35, P = 0.05). CONCLUSION It is possible to customize APD, where the tidal percentage coincides with the transition point for a given catheter and a specific initial dialysate fill volume, the tolerance of which can be measured by assessing IPP.

Published
2003

34. Vaginal colonization with group B Streptococcus (Streptococcus agalactiae) and peritonitis in a woman on CAPD

Author

M Surian, Paolo Grillo, R Scanziani, Sebastiano De Liso, Beatrice Dozio, Laura Colombo, and Ivano Baragetti

Subjects
Adult, medicine.medical_treatment, Colony Count, Microbial, Peritonitis, medicine.disease_cause, Group B, Microbiology, Peritoneal dialysis, Streptococcus agalactiae, Vaginal disease, Peritoneal Dialysis, Continuous Ambulatory, Streptococcal Infections, Medicine, Humans, Vaginitis, Transplantation, biology, business.industry, Streptococcus, medicine.disease, Streptococcaceae, biology.organism_classification, Nephrology, Immunology, Vagina, Female, business
Published
1999

35. Nonacidotic proximal tubulopathy transmitted as autosomal dominant trait

Author

Ivano Baragetti, Stefano Mora, Giacomo Dell'Antonio, Giuseppe Vezzoli, Giuseppe Bianchi, Laura Soldati, Simona Zerbi, Vezzoli, G, Zerbi, S, Baragetti, I, Soldati, L, Mora, S, Dell'Antonio, G, and Bianchi, G

Subjects
Adult, Male, Proband, Glycosuria, medicine.medical_specialty, Adolescent, Hypophosphatemia, urologic and male genital diseases, Absorption, Diagnosis, Differential, Kidney Tubules, Proximal, Kidney Calculi, Calcitriol, Tubulopathy, Internal medicine, medicine, Humans, Hypercalciuria, Child, Chronic Kidney Disease-Mineral and Bone Disorder, Reabsorption, business.industry, Autosomal dominant trait, Middle Aged, Fanconi Syndrome, medicine.disease, Pedigree, Endocrinology, Tubular proteinuria, Nephrology, Calcium, Female, Kidney Diseases, medicine.symptom, business
Abstract

The family of a patient with a nonacidotic and hypercalciuric proximal tubulopathy was studied. The proband showed glycosuria, aminoaciduria, tubular proteinuria, renal hypophosphatemia, and urate tubular hyporeabsorption without bicarbonate loss. He also presented increased urine calcium excretion, plasma 1,25-dihydroxyvitamin D, and enteral calcium absorption. Clinical consequences of the tubulopathy were osteopenia and calcium kidney stones. Fifteen of the proband's relatives were studied; six of them had renal hypophosphatemia, 10 presented hypercalciuria, and three showed both hypercalciuria and hypophosphatemia. No other reabsorption defects were observed. High plasma levels of 1,25-dihydroxyvitamin D were found in 13 family members; their values correlated positively with calcium excretion and negatively with tubular phosphate reabsorption. None produced stones or had reduced mineral bone density. Hypophosphatemia and hypercalciuria occurred in the two generations studied; their transmission was independent of gender, and male-to-male transmission occurred for both defects. Our findings suggest that a genetic alteration of proximal tubular function could cause multiple reabsorption defects in the proband or renal phosphate leakage in the proband's relatives. The genotypic alteration causing the proximal dysfunctions may be monogenic, with an autosomal dominant pattern of inheritance and variable expressivity. Increased calcium excretion may be due to the proximal tubular alteration; alternatively, it may be the result of a genetic background predisposing to idiopathic hypercalciuria. Phosphate and calcium loss could stimulate 1,25-dihydroxyvitamin D synthesis in proximal tubular cells.

Published
1997

36. Effect of vitamin B12 on homocysteine plasma concentration in hemodialysis patients

Author

Silvia Furiani, F. Bamonti Catena, Enzo Corghi, Gherardo Buccianti, Ivano Baragetti, and V. Dorighet

Subjects
medicine.medical_specialty, Homocysteine, business.industry, medicine.medical_treatment, General Medicine, chemistry.chemical_compound, Endocrinology, chemistry, Nephrology, Internal medicine, Plasma concentration, medicine, Hemodialysis, Vitamin B12, business
Published
2004
Full Text
View/download PDF

37. Vascular access - 1

Author

Utz Settmacher, Wu-Chang Yang, Michael Heise, A.R. Zarate, Luc Turmel-Rodrigues, Young Soo Kim, Daniele Ciurlino, Antonius Rabsch, R. Martínez-Cercós, Hidetoshi Kanai, Ramazan Kaya, O. Ibrik, Machiko Okamoto, Silvia Furiani, B. Rossi, Anna Bednarek-Skublewska, Cornelia Zierold, Samir S. Patel, Deven Juneja, Vincenzo La Milia, Suk Young Kim, Roland Kaufmann, Pierre Bourquelot, Serge Cournoyer, Tanja Roche, Sehmus Ozmen, Georgina Bailey, Hossam El-Shazly, George Stavgianoudakis, Nicole Daniel, Michele Roy, Margarita Villa, Alexander Koch, Petra Kirschner, George Soltys, Paraskevi Tseke, Lara Traversi, Mi Jung Shin, Zuhat Urzakci, Mayoor V. Prabhu, Lisa Savoie, Heather Duncan, M. Feriani, Violaine Begin, Michiya Shinozaki, Nestor Thereska, Nektaria Giapraka, Giorgia Bagiatudi, Elena Bruschetta, Francesco Locatelli, Sabina Libardi, Cheuk-Chun Szeto, Wojciech Załuska, Mohan Sathyanarayanan, Lambros Papatzikos, John Paul Killen, Sun Ae Yoon, Andrzej Ksiazek, R. Roca-Tey, Erjola Likaj, Yong Soo Kim, Mahmoud El-Khatib, F. Antonucci, Ahmet Duraku, Tokuya Nakahara, A. Rivas, Stephan Lotze, Christos Andriopoulos, Claudia Foltys, Visweswar Reddy Pachipala, Sridhar Gandhe, Ireen Töpfer, K.S. Nayak, Giuseppe Pontoriero, M. Nordio, Kai Ming Chow, J. Viladoms, Elisavet Stamataki, Ivano Baragetti, Tiziana Mazzullo, Chih-Ching Lin, Sreepada Subhramanyam, Myftar Barbullushi, N. Tessitore, Davut Akin, Giovanni Regine, Giuseppe Bacchini, Murty Mantha, Myeong A. Cheong, Philip Kam-Tao Li, Saimir Seferi, Silvio Bertoli, J.C. Romero, Sandra Dennler, Claudio Musetti, Young Ok Kim, I. Giménez, Julien Gaudric, Kenichi Oguchi, Marek Iłżecki, Prabir Roy-Chaudhury, E. Camerin, Mikiko Ayada, Charlotte Giroux, Konstantinos Salpiggidis, Stanisław Przywara, Palepu B Gopal, Sindy König, Yuet Ling Poon, Kenji Harada, Richard Baer, Manabu Asano, Ahsan Ullah, Evangelos Sarris, Ho Cheol Song, R. Samon, Enzo Corghi, Timmy Lee, G. Piccoli, Jan Tawakol, Claudio Pozzi, Elena Alberghini, Antono Carnabuci, Danai Stavrianaki, M. Raghavendran, Laura Buzzi, Elpida Kalyveza, Merita Rroji, Cristina Sarcina, Guyette Vallee, and Veronica Terraneo

Subjects
Transplantation, medicine.medical_specialty, Nephrology, business.industry, medicine, Vascular access, Intensive care medicine, business
Published
2009
Full Text
View/download PDF

38. Peritoneal dialysis - 1

Author

Fatma Eroglu, Claudio Pozzi, Hyunwook Kim, Claudio Ronco, Benjamin Zeier, Xueqing Yu, Dirk G. Struijk, Javier Ocaña, Roman Stankiewicz, Marilena Cara, Taner Camsari, Jun Wada, Susan Yung, Hung Shih-Yuan, Fu-Chang Hu, Michał Nowicki, Ni Gao, Denise E. Sampimon, Deirisa Lopes Barreto, Zulfikar Yilmaz, Martin Zeier, Johan V. Povlsen, Daniele Ciurlino, Zofia Wankowicz, Yu-Yin Tsai, Rungmei S. K. Marak, Renzo Scanziani, Chang Ming-Yu, Iraj Najafi, Xiao Yang, Kazumichi Matsushita, Show-Mei Nian, Tak Mao Chan, Chunyan Yi, Yung-Ming Chen, Manel Vera, Eduard Garcia, Cheng-Hsu Chen, Laura Buzzi, Jens Dam Jensen, Petar Kes, Hung-Chun Chen, Almudena Ortigosa, Zeljka Mustapic, Wing-Fai Pang, Paula López-Sánchez, Christian Thiede, Carlo Crepaldi, Vedat Schwenger, Marie-Luise Gross, Giovambattista Virga, Qingyu Kong, Aiping Gu, Jenq-Wen Huang, Manuel Corral, Gao Dan, Ching-Yuang Lin, Liang Xian-hui, Wim Van Biesen, Isao Araki, Tetsu Miyamoto, Ivana Jurić, Roberto Russo, Xiuqing Dong, Francisco Coronel, Erjola Likaj, Ramazan Cetinkaya, Wieslawa Lysiak-Szydlowska, Chi-Chih Hung, Uta Oelschlaegel, Cheuk-Chun Szeto, Shigeru Akagi, Yuji Takatori, Ulrike Haug, Chih-Kang Chiang, Julia Kerschbaum, Veysi Akpolat, Per Ivarsen, Qiang Yao, Elena Alberghini, Lee Yi-Jer, Claudio Musetti, Bengt Lindholm, Mei-Chuan Kuo, Paweł Stróżecki, Michael A. Rudnicki, Teresa Grzelak, Aiwu Lin, Catherine Chen, Lars P. Kihm, Young Chul Yoon, Masahito Tamura, Qing Zhang, Mihaela Petti, A. Lawerence, Dong Hyung Lee, Shih-Tin Huang, Jun Wu, Xinghui Lin, Beom Seok Kim, Luciana Bonfante, Elżbieta Marcinkowska, Mariapia Rodighiero, Marijke de Graaff, Silvia Furiani, June Fabian, Tatsuya Miyamoto, Elena Corchete, Myftar Barbullushi, Manabu Kamiyama, Anna Stefańska, Sandra Müller-Krebs, Shin Wook Kang, Hasan Kayabasi, Mercedes Velo, Enzo Corghi, Kai-Ming Chow, Zbigniew Heleniak, Nikolina Bašić-Jukić, Raymond T. Krediet, Constanze Meye, Min-Ju Wu, Zhao Zhanzheng, Ryota Serino, Pierluigi di Loreto, Nicole Ladeira, Monika Lichodziejewska-Niemierko, Nader Nouri-Majalan, Hoshang Sanadgol, Gülgün Oktay, Raj Kumar Sharma, Yoshiaki Doi, Beata Szary, Anupma Kaul, Katarzyna Osiewala, Ivano Baragetti, Shang-Jyh Hwang, Paul König, Kuo-Hsiung Shu, Kuan-Yu Hung, M. Emin Yilmaz, Francisco Maduell, Haeng Soon Jeong, Yumi Furuno, Maurizio Nordio, Andrea Wagner, Hameed Anijeet, Jacek Rysz, Hye Ran Kim, Xiaoyan Li, Philip Kam-Tao Li, Ilaria Serra, Zhaohui Ni, Ya-Wen Chuang, Ali Kemal Kadiroglu, Marta Arias, Vincenzo La Milia, Yucheng Yan, José Portolés, Jacek Manitius, Liu Zhangsuo, Sagren Naidoo, Snjezana Glavas-Boras, Aliyu Abdu, Bolesław Rutkowski, Chi-Hung Cheng, Juan M. López-Gómez, Chia-Te Liao, Kay Herbrig, Joanna Stachowska-Pietka, Mieko MIyazaki, Xin Wang, Peter Gross, Tun-Jun Tsai, Weiying Chen, Jacek Waniewski, Mario R. Korte, Efsun Kolatan, Dorota Bielińska − Ogrodnik, Keiichi Takiue, Tatsuya Shibata, Eun Young Kim, Isabel Devolder, Ho Li-Chun, Zahide Cavdar, Makoto Hiramatsu, Si Hyun Kim, Mayte Ribera, Marcia R. Gómez, Rafał Donderski, Sylwia Małgorzewicz, Shirin Malgas, Dede Sit, Dariusz Nowak, Hamidullah Uyanik, Tobias Drescher, Ming-Ju Wu, Annick Verleysen, Robert A. Stolarek, Junko Inoue, Aggrey Mweemba, Aleix Cases, Grzegorz Zelichowski, Krystyna Czyżewska, Ho Yung Lee, Nagahiro Sato, Yutaka Otsuji, Jeong Hwan Shin, Shoichiro Kojo, Jiaqi Qian, Yang Wook Kim, Jens Passauer, Johann Hausdorfer, Osman Yilmaz, Hirofumi Makino, Tae Ik Chang, Ahmet Duraku, Tzu-Hui Chen, Jianxiong Lin, Hitoshi Sugiyama, Magdalena Grajewska, J.M. Campsitol, Yeong Hoon Kim, Jung Tak Park, Raymond Vanholder, Chi-Bon Leung, Chen-Yen Kuo, Anniek Vlijm, Li Yan, Hsin-Hui Wang, Takashi Yamagishi, Jae Hyun Chang, Jin-Bor Chen, Antonio Alcaraz, Patricia de Sequera, Jolanta Fijalkowska, Wang Hsi-Hao, Anna Olszowska, Rammohan Bhat, Mizuya Fukasawa, Graham Paget, Jocelyn T Naicker, Saimir Seferi, Silvio Bertoli, Wei Fang, Gert Mayer, Ling Ye, Mustafa Keles, Su-Chu Lee, Masashi Suzuki, Kwan-Dun Wu, Saraladevi Naicker, Denise Sampimon, Shang-Chih Liao, Kyu Hun Choi, Bonnie Ching-Ha Kwan, Sarasadat Moghadasimousavi, Giorgio Vescovo, Adrianna Pedzik, Muhammad Imran, Weiming Zhang, Narutoshi Kabashima, Funda Saglam, Tae Hyun Yoo, Martin Bornhäuser, Tung-Min Yu, Ryoko Baba, Nestor Thereska, Sun Young Park, Masami Bessho, Sulen Sarioglu, Hamit Acemoglu, Hiroshi Morinaga, Kazushi Nakao, Abdullah Uyanik, Andrzej Werynski, Masayuki Takedda, Dong Ki Kim, Jeong Nyeo Lee, Bang-Gee Hsu, Bergadá E, Shouji Kudo, and Néstor Fontseré

Subjects
Transplantation, medicine.medical_specialty, Nephrology, business.industry, medicine.medical_treatment, medicine, Urology, business, Peritoneal dialysis
Published
2009
Full Text
View/download PDF

39. Study of calcium metabolism in idiopathic hypercalciuria by strontium oral load test

Author

Giuseppe Bianchi, Simona Zerbi, Laura Soldati, A. Centemero, Andrea Caumo, Ivano Baragetti, Alessandro Rubinacci, GianLuigi Moro, P. Bellinzoni, Donatella Adamo, and Giuseppe Vezzoli

Subjects
Adult, Male, medicine.medical_specialty, Clinical Biochemistry, Population, Administration, Oral, Parathyroid hormone, chemistry.chemical_element, Calcium, Enteral administration, Excretion, Internal medicine, medicine, Humans, education, Calcium metabolism, education.field_of_study, Chemistry, Biochemistry (medical), Middle Aged, Endocrinology, medicine.anatomical_structure, Strontium, Area Under Curve, Duodenum, Female, Hormone
Abstract

Calcium excretion and absorption were evaluated in hypercalciuric calcium stone formers by the study of Sr2+ excretion and absorption after an oral load. Ca2+ stone formers (n = 140) were studied, and the results were compared in the 83 of them who had idiopathic hypercalciuria and in the 57 who had Ca2+ excretion within reference values. Hypercalciuric patients showed increased renal Sr2+ clearance (CRE; 5.26 ± 0.358 vs 3.29 ± 0.277 mL/min; P

40. Improvement of endothelial function in uraemic patients on peritoneal dialysis: a possible role for 5-MTHF administration.

Author

Ivano Baragetti, Sara Raselli, Andrea Stucchi, Veronica Terraneo, Silvia Furiani, Laura Buzzi, Katia Garlaschelli, Elena Alberghini, Alberico L. Catapano, and Gherardo Buccianti

Subjects
*HOMOCYSTEINE, *HEMODIALYSIS, *FILTERS & filtration, *KIDNEY diseases
Abstract

Background. Hyperhomocysteinaemia is an independent risk factor for the development of atherosclerosis. Furthermore, homocysteine induces endothelial dysfunction by an increased inactivation of nitric oxide. In patients with chronic renal failure, the administration of folic acid or its metabolites reduces but does not normalize plasma homocysteine concentrations. Methods. We examined the effect of oral treatment with 15 mg/daily of 5-methyltetrahydrofolate (5-MTHF) for 12 weeks, on homocysteinaemia and endothelial function in 19 patients undergoing peritoneal dialysis and compared them, for the same period of time, to a control group of patients on peritoneal dialysis. Endothelial function was evaluated by B-mode ultrasonography on the brachial artery. Flow-mediated dilation (FMD) was recorded during reactive hyperaemia produced by the inflation of a pneumatic tourniquet. Nitroglycerine-mediated dilation (NMD) was recorded after sublingual administration of glyceryl trinitrate. Finally, oxidative stress was assessed by evaluating the conjugated dienes plasma levels. Results. Plasma homocysteine concentrations fell by 30% after oral treatment with 5-MTHF. Endothelial function improved significantly after oral 5-MTHF treatment (13.8 ± 1.2% vs 11.4 ± 1.4%; P P Conclusions. Our study demonstrated that 5-MTHF administration improves endothelial dysfunction in patients undergoing peritoneal dialysis. This effect appears to be independent of the reduction in homocysteine plasma levels. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results